Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
09/2012 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions September class, title,number 09/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
09/27/2012 > 160 patent applications in 116 patent subcategories. class, title,number

20120245076 - Compositions and methods for delivering rnai using apoe: This invention relates to the use of lipoproteins with oligonucleotides, both single and double stranded, and their use in delivering dsRNA for RNA interference. More specifically, the present invention relates to composititons containing oligonucleotides and alipoprotein E, which enables tissue-specific delivery and reduction of target expression.... Agent: Alnylam Pharmaceuticals, Inc.

20120245078 - Means and methods for treating ischemic conditions: The present invention relates to a combination of (a) at least one glucocorticoid; and (ba) at least one proteasome inhibitor and/or (bb) at least one nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation, for use in the treatment or prevention of ischemic disorders of... Agent:

20120245077 - Prokineticin 1 receptor: The present invention relates to methods of monitoring the biological activity of the PK1 receptor.... Agent:

20120245079 - Treatment of diseases caused by bacterial exotoxins: Provided are high affinity T cell receptor variable regions that are useful for treating diseases caused by superantigens including atopic dermatitis, pneumonia and delayed wound healing. The variable regions contain mutants that result in high affinity binding to the superantigen.... Agent:

20120245080 - Mineral salt-sulfonic acid compositions and methods of use: The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.... Agent: Bmg Pharma LLC

20120245081 - Fas peptide mimetics and uses thereof: Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions,... Agent: Trustees Of The University Of Pennsylvania

20120245082 - Novel antimicrobial activity of chicken nk-2 peptide against apicomplexan protozoa: NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora... Agent:

20120245083 - Derivatives of cgrp: Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments.... Agent: Novo Nordisk A/s

20120245084 - Formulations of diluted amino acid segments and methods for making same: A formulation of a diluted amino acid segment is prepared by mixing an amino acid segment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid segment includes a peptide sequence that is the same as a portion of... Agent: Deseret Biologicals, Inc.

20120245085 - Pharmaceutical solution of non covalently bound albumin and acylated insulin: If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection.... Agent: Novo Nordisk A/s

20120245086 - Wnt10-derived peptide and use thereof: The present invention relates to a WNT10-derived peptide, a composition for improving hair loss and skin conditions using the same, and a composition for treating a WNT10 signal transduction pathway-related disorder and DKK-1 protein-induced disorder using the same. WNT10-derived peptide of the present invention possesses identical or similar activities to... Agent: Caregen Co., Ltd.

20120245087 - Novel tissue protective erythropoietin receptor (nepor) and methods of use: There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a... Agent: Alepor Gmbh & Co. Kg

20120245088 - Compositions comprising igf1 agonists and uses thereof: Pharmaceutical compositions and methods for improving functional capacity of tissues and organs in both healthy and pathologic disease states for: reducing unwanted cosmetic effects of aging on the skin to reduce wrinkles, to increase collagen and water content, thicken and increase skin volume and to maintain a youthful appearance to... Agent:

20120245090 - Method for screening an agent being useful for the treatment of dry eye and / or corneal and conjunctival lesion and pharmaceutical composition obtained by the method: The present invention provides a method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to the report of the International Dry Eye WorkShop (DEWS Report) (2007) and a pharmaceutical composition comprising the... Agent: R-tech Ueno, Ltd.

20120245089 - Use of the sparc microenvironment signature in the treatment of cancer: The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies... Agent: Abraxis Bioscience, LLC

20120245091 - Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein... Agent: Supadelixir Inc.

20120245092 - Polypeptides having modulatory effects on cells: The present invention relates to peptides and polypeptides having the sequence SAVTFAVCAL or variants thereof, capable of binding to Calcineurin and/or to NS5A-TP2 and to their use in therapy, as well as to nucleic acid sequences and vectors encoding these peptides and polypeptides, and to cells comprising said polypeptides, nucleic... Agent: Ecole Normale Superieure De Lyon And Centro National De La Recherche Scientifique

20120245095 - Biglycan and related therapeutics and methods of use: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those... Agent: Brown University Research Foundation

20120245094 - Compounds, compositions and use: A peptide comprising a unit of formula (I) and having a molecular weight of less than 2000 wherein each X is independently an organic group, e.g. a C1-6 alkyl or C1-6 alkenyl group, preferably —CH2—CH═CH2, or the two X groups taken together can form a covalent or non-covalent link between... Agent:

20120245093 - Neuronal viability factor and use thereof: This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)

20120245096 - Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine... Agent: Allergan, Inc.

20120245097 - Use of pedf-derived polypeptides for promoting stem cells proliferation and wound healing: Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity... Agent:

20120245098 - Topical palmitoyl glutathione formulations: s

20120245099 - Apoptosis inducer: The present invention provides an apoptosis-inducing agent capable of inducing apoptosis in various cells including tumor cells and other cells in a simple manner, etc. The apoptosis-inducing agent of the present invention comprises a peptide shown in (a) or (b) below, a derivative thereof, or a salt of the peptide... Agent: Nihon University

20120245100 - Plasmid for expression of transgenes in plants: A plasmid for use in transferring a chicken anemia virus apoptin coding sequence into a plant includes a binary vector suitable for transferring DNA from Agrobacterium tumefaciens to a selected plant, upstream and downstream homologous regions for targeting transfer of the DNA to a specified location in the selected plant... Agent:

20120245101 - Synthetic apolipoprotein e mimicking polypeptides and methods of use: The present invention provides novel synthetic apolipoprotein E (ApoE)-mimicking peptides wherein the receptor binding domain of apolipoprotein E is covalently linked to 18A, the well characterized lipid-associating model class A amphipathic helical peptide, or a modified version thereof. Such peptides enhance low density lipoprotein (LDL) and very low density lipoprotein... Agent:

20120245102 - Partial peptide of lacritin: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.... Agent: Senju Pharmaceutical Co., Ltd.

20120245103 - Silk proteins: The present invention provides silk proteins, as well as nucleic acids encoding these proteins. The present invention also provides recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the manufacture of personal care products, plastics,... Agent:

20120245104 - Novel retro-inverso leptin peptide antagonists: Disclosed herein are peptides comprising a leptin sequence and methods for their use in preventing ObR signaling in a leptin-responsive cell. A leptin peptide of the present invention binds to but does not activate ObR signaling in a leptin-responsive cell, thereby inhibiting the up-regulatory effects of leptin on ObR signaling... Agent:

20120245105 - Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors: Methods, compositions and articles of manufacture for contributing to the treatment of a solid cancerous tumor are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery of a chemotherapeutic agent to a solid tumor in mammals, including humans.... Agent:

20120245106 - Modified lysine-mimetic compounds: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.... Agent: Zealand Pharma A/s

20120245107 - Methods of reducing the proliferation and viablility of microbial agents: The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents.... Agent: Targeted Delivery Technologies Limited

20120245109 - Antithrombotic dual inhibitors comprising a biotin residue: The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombosis or other thrombin-related diseases. The antithrombotic activity of the compound of this invention can be neutralized in case of emergency upon adminstration of avidin, streptavidin and analogues thereof having high biotin affinity.... Agent: Msd Oss B.v.

20120245108 - Method of modulating complement factor b (cfb) expression in cells: The present invention relates to a method of modulating complement factor B (CFB) expression in cells, comprising administering an effective amount of tannic acid to the cells. This method can be applied in treating or prophylaxis of the disease, disorder or medical condition associated to complement factor B (CFB) expression.... Agent: Kaohsiung Medical University

20120245110 - Vascular leakage inhibitor: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions... Agent:

20120245113 - Clerodane derivatives for modulation of leukotriene receptor activity and related diseases: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against... Agent: Biotropics Malaysia Bhd

20120245111 - Flavanones-containing food compositions: The present invention relates to food products comprising flavanones. In particular, it relates to food products comprising hesperidin having improved stability. The present invention also concerns processes for the manufacturing of food products comprising said flavanones, especially hesperidin and to the use of the food products in the manufacture of... Agent: Nestec S.a.

20120245112 - Synthesis and identification of novel rsk-specific inhibitors: A composition comprising an SL0101 [kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the... Agent:

20120245114 - Method for the protection of trees: The present invention provides a method for the prevention/treatment of bark beetle and/or wood borer infestation of trees comprising treatment of the tree with a composition comprising a macroyclic lactone.... Agent: Syngenta Crop Protection LLC

20120245115 - 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.... Agent: Cortria Corporation

20120245116 - Inhibiting gs-fdh to modulate no bioactivity: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.... Agent: Duke University

20120245216 - Compositions and methods for treatment of neuropathic pain: The present invention relates to compounds, compositions, methods, systems and kits for treating neuropathic pain regulated by SIP30. The present invention provides SIP30 antagonists for the treatment of neuropathic pain.... Agent: Rutgers, The State University Of New Jersey

20120245217 - Rnai-mediated inhibition of hif1a for treatment of ocular angiogenesis: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.... Agent: Alcon Research, Ltd.

20120245221 - Anti-apoptotic agents and uses thereof: The invention generally relates to the use of parasite-derived neurotrophic factor (PDNF), or a fragment of PDNF, to reduce cell apoptosis. The PDNF or PDNF fragment is provided in the cytoplasm of a cell so that it can bind to Akt kinase and induce Akt kinase activation.... Agent: Tufts University

20120245219 - Minor groove binder (mgb)-oligonucleotide mirna antagonists: Compositions and methods for inhibiting the actions of non-coding RNAs such as miRNAs and piRNAs are provided. The compositions comprise single or double stranded oligonucleotides conjugated with Minor Groove Binders (“MGBs”). The oligonucleotides can vary in length, can contain nucleotides having one or more modifications, and have regions that are... Agent: Elitech Holding B.v.

20120245220 - Nucleic acid molecules and methods for exchanging exon(s) by transsplicing: The present invention provided methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated simple or double trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and to mediate a simple or double trans-splicing... Agent: Association Institut De Myologie

20120245218 - Surface modified nanoparticles, methods of their preparation, and uses thereof for gene and drug delivery: A composition comprises a surface modified nanoparticle comprising a core comprising a material selected from the group consisting of organic materials, organometallic materials, inorganic materials, metals, metal oxides, and combinations thereof; and a surface branch covalently linked to the core having the general formula (3):... Agent: International Business Machines Corporation

20120245118 - Methods and compositions for alleviating stuttering: Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class... Agent: Endo Pharmaceuticals Solutions Inc.

20120245117 - Methods of treating squamous cell lung cancer with 4-iodo-3-nitrobenzamide in combination with gemcitabine and carboplatin: In one aspect, the present invention provides a method of treating squamous cell lung cancer in an individual comprising administering to the individual having lung cancer an effective amount of 4-iodo-3-nitrobenzamide or a metabolite thereof or pharmaceutically acceptable salt thereof; gemcitabine; and carboplatin.... Agent:

20120245119 - Method for separating sialyllactose material: A method for easily and efficiently separating a sialyllactose material from a milk material is disclosed. The method comprises removing proteins from the milk material to obtain a protein-free liquid, adjusting the pH of the protein-free liquid to obtain a pH-adjusted liquid, and concentrating the pH-adjusted liquid by an ultrafiltration... Agent: Megmilk Snow Brand Co., Ltd.

20120245120 - Zinc sucrose octasulfates, their preparation, and pharmaceutical and cosmetic uses thereof: m

20120245122 - Carotenoid-containing compositions and methods: The present invention is directed to carotenoid-containing compositions and methods for improving bone or respiratory health in a subject comprising administering to the subject a combination of lycopene, beta-carotene, and beta-cryptoxanthin.... Agent:

20120245121 - Methods for improving bone health in infants using long chain polyunsaturated fatty acids: Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding... Agent: Abbott Laboratories

20120245123 - Methods for improving bone health in infants using prebiotics: Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including a prebiotic to a woman during pregnancy and optionally during lactation and breastfeeding of an... Agent: Abbott Laboratories

20120245125 - Pyridazine compounds, compositions and methods: The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation... Agent: Northwestern University

20120245124 - Trpv3 modulators: e

20120245126 - Divalent and oxabridged heterocyclic neonicotinoid compounds and preparation methods thereof: Nitromethylene analogues of imidacloprid and divalent and oxabridged heterocyclic neonicotinoid compounds constructed by dialdehydes, preparation methods and uses thereof are disclosed. Compounds represented by formula (A) or (B), their optical isomers or agrochemically acceptable salts are provided. Agrochemical compositions comprising the said compounds, their optical isomers or agrochemically acceptable salts,... Agent: East China University Of Science And Technology

20120245127 - Methods of treating cell proliferative disorders: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.... Agent: Rigel Pharmaceuticals, Inc.

20120245128 - Rapid detection and quantification of modification of medicinal compounds and drug resistance activity: The present disclosure in general relates to methods, systems, and apparatus for identifying modification of a medicinal compound exposed to a sample for use in determining which treatment to provide to a subject in need thereof.... Agent: The Board Of Regents Of The University Of Texas System

20120245129 - Use of s1p receptor modulator: Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression.... Agent:

20120245130 - Methods of using substituted tetracycline compounds to modulate rna: A method for modulating RNA with tetracycline compounds is described.... Agent: Paratek Pharmaceuticals, Inc.

20120245131 - 6-substituted estradiol derivatives for use in remyelination of nerve axons: m

20120245132 - Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof: The present invention relates to the use of low content of benzoic acid and/or sodium salt thereof in combination with one or more organic acid preservatives as active ingredients in the manufacture of a vaginal composition, wherein the composition has weak inhibition effect on normal vaginal lactobacilli while has strong... Agent:

20120245133 - Methods for the treatment of a traumatic central nervous system injury: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of... Agent: Emory University

20120245134 - Androgen pharmaceutical composition and method for treating depression: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a... Agent:

20120245135 - Gallium complexes, pharmaceutical compositions and methods of use: The present invention provides complexes of gallium with a ligand, methods of making the complexes, methods of using the complexes and pharmaceutical gallium compositions comprising the complexes, in particular those compositions suitable for therapeutic oral administration.... Agent: Genta Incorporated

20120245137 - Aryl sulphone derivatives as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity, are disclosed. Specifically, a series of compounds containing aryl sulphone derivatives, as exemplified by Formula (I).... Agent: Zalicus Pharmaceuticals Ltd.

20120245139 - Inhibitors of the hedgehog pathway: t

20120245138 - N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl arylsulfonamides: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as... Agent: Chemocentryx, Inc.

20120245140 - N-containing heteroaryl derivatives as jak3 kinase inhibitors: N-containing heteroaryl derivatives of formula I or II, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK, particularly JAK3, kinase inhibitors.... Agent:

20120245141 - Activators of human pyruvate kinase: Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R1 to R16 are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

20120245136 - Chroman-spirocyclic piperidine amides as modulators of ion channels: The invention relates to chroman spirocyclic piperidine amide derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent:

20120245143 - 3-0x0-2,3-dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition: There are provided substituted 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide derivatives (I) which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The... Agent: Nerviano Medical Sciences S.r.l.

20120245142 - 3-oxo-2,3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors: There are provided substituted 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide derivatives (I) which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The... Agent: Nerviano Medical Sciences S.r.l.

20120245144 - Benzoxazepin compounds selective for pi3k p110 delta and methods of use: Benzoxazepin Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in... Agent: Genentech, Inc.

20120245145 - Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker: In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions that is caused by any... Agent:

20120245146 - Method of treatment of hormone depletion induced vasomotor: The invention provides a method to effectively wean a woman from hormone therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for... Agent:

20120245147 - Inhibitors of thapsigargin-induced cell death: Methods for screening for inhibitors of endoplasmic reticulum (ER) stress are provided. These methods involve the addition of thapsigargin, which induces ER stress, and a test agent to mammalian cells in multi-well plates. Cell survival can be readily monitored by measuring intracellular ATP content using a bioluminescent reagent. Screening a... Agent:

20120245149 - Novel (heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors: t

20120245150 - Novel (heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors:

20120245148 - Tetrahydroquinoxaline uera derivatives, their preparation and their therapeutic application: The present invention relates to tetrahydroquinoxaline urea derivatives, to their preparation and to their therapeutic application.... Agent: Sanofi

20120245151 - Bisfluoroalkyl-1,4-benzodiazepinone compounds: wherein: R1 is —CH2CF3 or —CH2CH2CF3; R2 is —CH2CF3, —CH2CH2CF3, or —CH2CH2CH2CF3; R3 is H or —CH3; each Ra is independently F, Cl, —CN, —OCH3, and/or —NHCH2CH2OCH3; and z is zero, 1, or 2. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions... Agent: Bristol-myers Squibb Company

20120245152 - 3-(biaryoxy)propionic acid derivative: [wherein, R1 represents a halogen atom, or the like, R2 represents a hydrogen atom, or the like, R3 and R4, each independently, represent a hydrogen atom, a C1-4 alkyl group, or the like, R5 represents a hydrogen atom, a halogen atom, or the like, R6 represents a hydrogen atom, a... Agent: Daiichi Sankyo Company, Limited

20120245155 - Fused heterocyclic compound having amino group: h

20120245153 - Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction: Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and use thereof.... Agent: Vanderbilt University

20120245154 - Substituted aminothiazine derivative: The present invention relates to an agent for treating or preventing disease induced by production, secretion and/or deposition of amyloid β protein, for example, a compound of formula (I), wherein, R1, R2a, R2b R3, R4a, R4b, ring A, and dashed line are described in this specification, its pharmaceutically acceptable salt... Agent: Shionogi & Co., Ltd.

20120245156 - Oral lyophilized compositions: e

20120245157 - Oxazine derivatives:

20120245159 - Composition and method for controlling arthropod pests: The present invention provides: an arthropod pests control composition comprising, as active ingredients, a condensed heterocyclic compound and a neonicotinoid compound; a method for controlling arthropod pests which comprises applying effective amounts of a condensed heterocyclic compound and a neonicotinoid compound to the arthropod pests or a locus where the... Agent: Sumitomo Chemical Company, Limited

20120245158 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the Formula I: Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of Formula I.... Agent:

20120245160 - Polymorphous forms iii and iv of n-benzoyl - staurosporine: The present invention relates to a crystalline form III and a crystalline form IV of N-benzoyl staurosporine. N-benzoyl staurosporine is also known as Midostaurin or PKC412.... Agent:

20120245161 - Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors: e

20120245162 - Oxadiazole inhibitors of leukotriene production:

20120245163 - Trpv1 antagonists:

20120245164 - Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators: The invention relates to a formula (I), in which R is a hydrogen or halogen atom or a (C1-C6)alkyl group; X is one or more substituents selected from a hydrogen or halogen atom, a (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, cyano, hydroxy, or hydroxy(C1-C6)alkyl group; Y is a hydrogen or halogen atom... Agent: Sanofi

20120245165 - Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof: The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory... Agent: Medifron Dbt Co., Ltd.

20120245166 - Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such: Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human... Agent: Southern Research Institute

20120245167 - Arthropod pest control method and composition: Disclosed is a harmful arthropod control composition comprising, as an active ingredient, a fused heterocyclic compound represented by formula (1) [wherein A1 and A2 independently represent a nitrogen atom or the like; R1 and R4 independently represent a halogen atom or the like; R2 and R3 independently represent a halogen... Agent: Sumitomo Chemical Company, Limited

20120245171 - Benzpyrazole derivatives as inhibitors of pi3 kinases: s

20120245169 - Certain chemical entities, compositions and methods: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.... Agent:

20120245168 - Composition, synthesis, and use of new substituted pyran and pterin compounds: The present invention relates to substituted pterin compounds, their synthesis and use. In particular, the present invention relates to a new precursor compound and its analogs for synthesizing a new substituted pterin compound and its analogs. These new compounds are particularly suitable for treating molybdenum cofactor deficiency.... Agent: Duquesne University Of The Holy Ghost

20120245170 - Pyrazolopyridine derivatives as anticancer agent: The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent.... Agent: Pierre Fabre Medicament

20120245174 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on each of BRaf and c-Raf-1 protein kinase, and may also... Agent: Plexxikon Inc.

20120245172 - Heterocyclic amine derivatives: Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease,... Agent:

20120245173 - Inhibition of activated cdc42-associated kinase 1: Compounds, compositions, and methods for specific inhibition of activated cdc42-associated kinase 1 (Ack1) are provided.... Agent: Fox Chase Cancer Center

20120245175 - Mk2 inhibitors: The present invention relates to compounds of general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used in the treatment of immune, autoimmune, inflammatory diseases, cardiovascular diseases, infectious diseases, bone resorption disorders, neurodegenerative diseases or proliferative diseases.... Agent: N.v. Organon

20120245178 - Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.... Agent:

20120245177 - Crystalline levofolinic acid and process for its preparation: The present invention relates to stable crystalline (6S)—N(5)-formyl-5,6,7,8-tetrahydrofolic acid, commonly referred to as levofolinic acid, in essentially pure 6S diastereomeric form, and to a process for its preparation.... Agent: Gmt Fine Chemicals Sa

20120245176 - Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals: e

20120245179 - Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as... Agent: Map Pharmaceuticals, Inc.

20120245180 - Combination: The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a novel combination comprising the MEK inhibitor: N-{3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and the PI3 kinase inhibitor: 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or... Agent: Glaxosmithkline LLC

20120245181 - Opioid receptor ligands and methods of using and making same: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.... Agent: Trevena, Inc.

20120245182 - Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-urea and salts thereof: The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its monophosphoric acid salt, and the hydrochloride salt, including its dihydrate. The present technology further provides methods for preparing the various forms, compositions containing them, and methods of treatment employing them.... Agent:

20120245183 - Macrocyclic lactone derivatives for the treatment of cancer: The present invention provides compounds represented by formula (1): wherein, R1, R2, R3 and R4 are as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. The invention also... Agent: Piramal Life Sciences Limited

20120245184 - Small organic molecule regulators of cell proliferation: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a compound. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal... Agent: Aderans Research Institute, Inc.

20120245185 - Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction: In one aspect, the invention relates to sulfone compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders... Agent: Vanderbilt University

20120245186 - Combination cancer therapy with hsp90 inhibitory compounds: Disclosed is a method for treating a subject with cancer, comprising administering to the subject an effective amount of paclitaxel or a paclitaxel analogue and an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the... Agent: Synta Pharmaceuticals Corp.

20120245187 - Heterobicyclic carboxamides as inhibitors for kinases: and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative... Agent: Novartis Ag

20120245188 - Methods of treating memory loss and enhancing memory performance: The present invention provides methods and compositions for enhancing working memory impaired due to aging, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, alcoholism or alcohol withdrawal or Huntington's disease using p38 MAPK inhibitor such as SB239063.... Agent: Translational Genomics Research Institute

20120245189 - Crystalline cdc7 inhibitor salts: The present invention relates to novel crystalline salts of a CDC7 or CDC7/CDKs inhibitor, to a novel crystal form of the corresponding free base, to a process for their preparation, to hydrates, solvates and polymorphs of such new salt forms, to their use in therapy and to pharmaceutical compositions containing... Agent: Nerviano Medical Sciences S.r.l.

20120245190 - Autophagy inducing compound and the uses thereof: the pharmaceutically-acceptable carrier, solvent, or the salts thereof which is used to treat autophagy-associated diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. The present invention also relates to a method of treating these diseases by administering a therapeutically-effective amount of the compound to the subject in need of... Agent: Hong Kong Baptist University

20120245191 - New azaspirodecanone compounds: e

20120245192 - Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease: Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form β, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms... Agent: Alfa Wassermann, S.p.a.

20120245193 - Peripherially acting μ opioid antagonists: s

20120245194 - Small molecule inhibitors of the alpha4-paxillin interaction: The present invention is directed to novel compounds that are able to inhibit the interaction of paxillin or its paralogues, including leupaxin or Hic-5, with alpha.4 integrin or its binding partners that regulate signaling events downstream of the paxillin-alpha.4 interaction. The present invention further relates to methods for therapeutic use... Agent: University Of California Technology Transfer

20120245195 - Novel monohydrate of azaadamantane derivatives: The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.... Agent: Abbott Laboratories

20120245196 - 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders: This invention provides 2-azabicyclo[3.1.1]heptyl derivatives, and methods for producing them, which are useful therapeutic agents for preventing or treating central nervous system disorders and disease mediated by a Nicotinic Acetylcholine Receptor such as, but not limited to, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, dementia, pain and nicotine addiction.... Agent:

20120245198 - Compounds and compositions for treatment of cancer: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.... Agent: Sunesis Pharmaceuticals Inc.

20120245197 - Pharmaceutical composition containing tosufloxacin or salt thereof: A pharmaceutical composition containing tosufloxacin or a salt thereof, which is excellent in stability and preservative effect and contamination preventing effect is provided. A pharmaceutical composition containing tosufloxacin or a salt thereof, a metal compound comprising aluminum, borax, an alkali metal chloride and a preservative is excellent in stability and... Agent: Toyama Chemical Co., Ltd.

20120245199 - [4 [4-(aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof: The present invention relates herein to compounds and compositions for the treatment and amelioration of inflammatory disease. Specifically the present invention relates to compounds that having a tryptase inhibition activity and the intermediates thereof, pharmaceutical compositions comprising such compounds, and a method of treating subjects suffering from a condition disease... Agent: Sanofi

20120245200 - Crystal form of quinoline compound and process for its production: e

20120245201 - Isopropylphenidate for treatment of attention-deficit/hyperactivity disorder and fatigue-related disorders and conditions: The present invention relates to the identification of isopropylphenidate as a useful therapeutic agent in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as well as various fatigue causing disease and disorders and medication induced fatigue.... Agent:

20120245202 - Methods and products for treating inflammation: Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(−)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such... Agent: Rock Creek Pharmaceuticals, Inc.

20120245203 - Methods for treating heartburn and/or preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy: The present invention relates to methods of treating heartburn in a patient receiving clopidogrel therapy. In another aspect, the present invention relates to methods of preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy.... Agent: Takeda Pharmaceuticals U.s.a., Inc.

20120245204 - Unknown: e

20120245205 - Compositions and methods for inhibiting hair growth: A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further... Agent:

20120245206 - Multi-cyclic compounds and methods of use: wherein B1, B2, B3, B4, C1, C2, ring D, L1, L2 and R1-4 are defined herein, synthetic intermediates, and pharmaceutical compositions, comprising such compounds. The compounds and compositions are capable of modulating various protein kinase receptors such as Tie-2 and Aurora and, therefore, influencing kinase related disease states and conditions.... Agent: Amgen Inc.

20120245207 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent:

20120245208 - 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives: The present invention relates to 2-oxo-1-pyrrolidine imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Ucb Pharma, S.a.

20120245209 - Heterocyclic sulfonamide derivatives: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation).... Agent: Novartis Ag

20120245210 - Novel thiophene inhibitors of s-nitrosoglutathione reductase: The present invention is directed to novel thiophene inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, LLC

20120245211 - Methods of treating cognitive dysfunction by modulating brain energy metabolism: Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed.... Agent: University Of Cincinnati

20120245212 - Controlled release carvedilol formulation: A controlled release carvedilol formulation for less frequent, preferably once daily administration is described. The controlled release formulation comprises a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt thereof, a matrix forming polymer, a solubility enhancer and a pharmaceutically acceptable carrier. In one embodiment, a controlled release formulation... Agent: Tsh Biopharm Corporation Ltd.

20120245213 - Human type i taste receptor subunit 3 modulators and methods of using same: Methods and compositions are provided for modulating the activity of human type I taste receptor subunit 3 (hT1R3). Such materials and methods are useful for the screening and preparation of compositions and methods for the treatment of carbohydrate and lipid metabolic diseases and disorders.... Agent:

20120245214 - Slow infusion of sulcardine and its salts: A composition comprised of an active agent that is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide or a pharmaceutically acceptable salt thereof is intravenously administered to a subject, substantially evenly over a period of greater than about 15 minutes, to avoid disadvantageous hemodynamic effects, including systemic diastolic and systolic hypotension, to can occur with... Agent:

20120245215 - Co-crystals of pyrrolidinones: The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R1 is a C-1 -C6 alkyl group. R is a C-1-C6 alkyl group which is optionally substituted by 1 to 3 halogens or R2 is a C2-C6 alkenyl group.... Agent: Ucb Pharma, S.a.

20120245222 - Methods of using low-dose doxepin for the improvement of sleep: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).... Agent: Somaxon Pharmaceuticals, Inc.

20120245223 - Use of gymnodimine, analogues and derivatives for the treatment and/or prevention of neurodegenerative diseases associated with tau and b-amyloid: t

20120245224 - Cannabinoids for use in the treatment of neuropathic pain: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds... Agent: Gw Pharma Limited

20120245225 - Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof: The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory... Agent: Medifron Dbt Co., Ltd.

20120245226 - Methods for treating attention-deficit/hyperactivity disorder: The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.... Agent:

20120245227 - Pharmaceutical compositions having desirable bioavailability: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as... Agent:

20120245228 - Methods and compositions for the generation of peracetic acid on site at the point-of-use: Methods and compositions for the generation of a peroxyacetic acid sanitizer in proximity to the point-of-use are disclosed. These methods comprise introducing a hydrogen peroxide-acetyl precursor solution to water, mixing, and then adding an aqueous source of a alkali metal or earth alkali metal hydroxide. Triacetin is a preferred acetyl... Agent:

20120245229 - Method for treating neuropathic pain: The invention describes a method to treat neuropathic pain and/or inflammatory pain, comprising the step of administering to a subject in need thereof an effective amount of a resolvin, such that neuropathic pain and or inflammatory pain is treated.... Agent:

20120245230 - Method and composition for preparing stable liquid formulations of paracetamol: The present invention relates to stable liquid formulations of paracetamol for pharmaceutical use and to a method of preparation of stable paracetamol solutions.... Agent: Tecnimede-sociedade Tecnico- Medicinal, S.a.

20120245231 - Weight based dosing of an oral solution having diphenhydramine, or pharmaceutically acceptable salts thereof, as an active ingredient: The present invention is directed toward a method of administering an oral solution containing one or more active ingredients, preferably formulations for non-prescription medicines, vital fluids, and/or nutritional supplements, optimally dosed based upon a patient's weight. The method includes providing an oral solution having an effective amount of one or... Agent:

20120245232 - Emulsifiable concentrate for a phytosanitary composition, phytosanitary composition and phytosanitary film: An emulsifiable concentrate for emulsified phytosanitary composition, including more than 90% by weight of at least one mixture of hydrocarbons having a distillation cut greater than 250° C., less than 20% by weight of n-paraffins and less than 1% aromatics, and from 1 to 4% by weight of a mixture... Agent: Total Raffinage Marketing

20120245233 - Crosslinked pigment dispersion based on structured vinyl polymeric dispersants:

20120245234 - Cosmetic and dermatologic composition and uses thereof: The present invention relates to a novel natural composition comprising sclerotium gum, xanthan gum and pullulan and intended for preparing cosmetic and dermatologic compositions, to the uses thereof, and to the cosmetic and dermatologic compositions containing said novel natural composition.... Agent: Lucas Meyer Cosmetics

20120245235 - Classification of cancers: A system for classifying a patient's cancer as belonging to one or more Cancer Modules of 1 of 15 different cancer types is provided. The Cancer Modules are useful to identify patient populations and individual patients demonstrating specific prognosis, risk of metastasis and/or recurrence, response or lack of response to... Agent: Compenda Bioscience, Inc

  
09/20/2012 > 158 patent applications in 128 patent subcategories. class, title,number

20120238488 - Compounds and methods for treating neoplasia: The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.... Agent:

20120238489 - Method for improving functional properties by means of pulsed light, samples with improved functional properties and uses thereof: Disclosed is a method for improving the functional properties of a sample, which comprises at least one component that can be modified upon absorbing ultraviolet light, the method including using pulsed light with an emission spectrum of 190-1100 nm and a high content of ultraviolet light to modify the component.... Agent:

20120238487 - Polymer composition useful as a pharmaceutical carrier: A polymer having a structure according to the following formula (I): wherein: A represents a hydrophilic group; B represents a hydrophobic aromatic group such as 5-dimethylamino-1-naphthalenesulfonyl (Dansyl), 9-fluorenylmethoxy carbonyl (Fmoc) and naphthalene (Naphth); D and E independently represent amine groups; F represents an amine group, the amine group being substituted... Agent: Robert Gordon University

20120238490 - Methods and compositions for the treatment of metabolic disorders: Embodiments described herein are directed to methods for the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, including atherosclerosis and non-insulin dependent diabetes. In addition, embodiments are... Agent:

20120238491 - Immunologically active lipopeptides and methods for use thereof: The present invention relates to the isolation and structure elucidation of 1-peptidyl-2-arachidonoyl-3-stearoyl glyceride (pDAG) as an active chemical entity in the caprine serum fraction, and the discovery of the innate immune modulating activity of pDAG as an endogenous damage associated molecular pattern... Agent: Therimunex Pharmaceuticals, Inc.

20120238492 - Fish protein hydrolysate for the use thereof in inhibiting weight gain and/or weight loss: The protein hydrolysates according to the invention are obtained by the enzymatic hydrolysis of at least one protein source selected from among the group comprising the following fish: Micromesistius poutassou, Clupea harengus, Scomber scombrus, Sardina pilchardus, Trisopterus esmarki, Trachurus spp., Gadus morhua, Pollachius virens, Melanogrammus aeglefinus, Coryphaenoides rupestris, fish belonging... Agent:

20120238493 - Glucagon analogs exhibiting gip receptor activity: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.... Agent:

20120238494 - Methods for reducing gnrh-positive tumor cell proliferation: A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells including those originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore, a method for reducing degenerate GnRH-positive... Agent:

20120238495 - Novel cellular factor-containing solution compositions: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.... Agent:

20120238496 - Fusion protein regulating plasma glucose and lipid, its preparation method and use: Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.... Agent: Chongqing Fagen Biomedical Inc.

20120238497 - Glp-1 fusion peptides, their production and use: The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or... Agent:

20120238498 - Agent for the treatment of alopecia: The solution means of the present invention is an agent for the treatment of alopecia containing as an active ingredient a C-type natriuretic peptide (CNP), a B-type natriuretic peptide (BNP), a derivative of these NPs, a chimeric peptide of these NPs, or a derivative of a chimeric peptide of these... Agent: Igisu Co., Ltd.

20120238499 - Methods of modulating apoptosis by administration of relaxin agonists or antagonists: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist... Agent: Molecular Medicine Research Institute

20120238500 - Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto: The present application is directed to the discovery that preparations of hedgehog polypeptides can be used to control the formation and/or maintenance of epithelial tissue.... Agent: Curis, Inc.

20120238501 - Modulation of osteoclast differentiation: The present invention concerns the use of an aquaprin-9 (AQP-9) modulator for the preparation of a pharmaceutical composition for treating or preventing a pathological condition associates with unbalanced osteoclast differentiation. In accordance with one embodiment, the modulator is an AQP-9 inhibitor. An example of an inhibitor is phloretin which was... Agent: Nitzozot Ltd.

20120238502 - Anti-fibrotic hydrogel compositions: A cross linked recombinant gelatin composition for the controlled release of a cellular adhesion inhibitory agent.... Agent:

20120238503 - Human laminin alpha2 chain lg3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth: The present invention relates to human laminin α2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin α2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading,... Agent: Snu R&db Foundation

20120238504 - Stable formulations of botulinum toxin in hydrogels: The invention includes liquid formulations of botulinum toxin, including hydrogel formulations that are stable to storage in liquid form at standard refrigerator temperatures for at least 1-2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for... Agent: Solstice Neurosciences, LLC

20120238505 - Medicaments: The present invention relates to the use of a peptide, or derivative thereof of general formula X1-X2-X3-ThT-X4-LyS-X5-ATg-X6 for promoting accelerated wound healing with reduced scarring. X1 is Ala or Gly; X2 is Tyr or Phe; X3, X4 and X5 are independently selected from the group comprising Met, He, Leu and... Agent: Renovo Limited

20120238506 - Acacia macrostachya seed extract and compositions containing same: The invention relates to a composition containing an extract of seeds of Acacia macrostachya. Advantageously the composition is cosmetic, pharmaceutical, dermatological or nutraceutical. The invention also relates to a method for extracting a Acacia macrostachya seed extract, as well as to the resulting extract. The invention further relates to one... Agent: Laboratoires Expanscience

20120238507 - Alpha helical mimics, their uses and methods for their production: Disclosed are short chain peptides that are constrained to adopt an alpha helicial conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides. Also disclosed is the use of these peptides for attaching peptidic... Agent: The University Of Queensland

20120238508 - Methods for promoting wound healing and/or reducing scar formation: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.... Agent:

20120238509 - Urocortin 2 analogs and uses thereof: Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing... Agent: Research Development Foundation

20120238511 - 2-deoxy-d-glucose formulations for prevention or treatment of neurodegenerative diseases: Pharmaceutical compositions containing 2-deoxy-D-glucose (2-DG) and methods of use for promoting neurological health and prevention of age-related neurodegeneration, such as Alzheimer's disease (AD), have been developed. The compositions may be formulated such that the composition, or the compound when release from the composition, crosses the blood-brain-barrier and promote neurotrophism and... Agent: University Of Southern California

20120238510 - Crystalline form of benzylbenzene sglt2 inhibitor: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are... Agent: Theracos, Inc.

20120238512 - Antithrombotic dual inhibitors comprising a biotin residue: The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa... Agent: Msd Oss B.v.

20120238513 - Method for inhibiting activation of macrophages: Provided is a method for inhibiting the activation of macrophages in a subject, comprising administrating to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable ester of the... Agent: China Medical University

20120238515 - Methods for preventing or treating sarcopenia and muscle atrophy in animals: The invention provides methods for one or more of preventing or treating sarcopenia and muscle atrophy in animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day.... Agent:

20120238514 - Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use: e

20120238516 - Granulated anthelmintic preparations and delivery systems: The present invention relates to anthelmintic compositions comprising two or more anthelmintic active agents selected from one or more of the following groups; imidazothiazoles such as levamisole, benzimidazoles such as oxfendazole, or fenbendazole, macrocylic lactones such as ivermectin or avermectin, salicylanilides, and praziquantel. The composition being in the form of... Agent:

20120238517 - Insecticidal compounds based on isoazoline derivatives: The present invention relates to compounds of formula (I): Wherein A1, A2, A3, A4, G1, L, Y1, Y2, Y3, Y4, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to intermediates for preparing compounds of formula (I),... Agent: Syngenta Crop Protection LLC

20120238518 - Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer: Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N2O2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and/or a decreased level of one or more... Agent: The United States Of America, As Represented By The Secretary, Dept Of Health And Human Services

20120238519 - Ophthalmic composition containing alginic acid or salt thereof: An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B)... Agent: Rohto Pharmaceutical Co., Ltd.

20120238619 - Micro-rna for the regulation of cardiac apoptosis and contractile function: The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing age-related cardiomyopathy include administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. Also provided herein... Agent: Miragen Therapeutics

20120238617 - Microrna expression signature in peripheral blood of patients affected by hepatocarcinoma or hepatic cirrhosis and uses thereof: A method for diagnosing or prognosticating hepatocellular carcinoma, also in the early stages, or for assessing the risk of developing hepatocellular carcinoma, or for monitoring the effectiveness of an anti-tumour therapy against hepatocellular carcinoma by measuring the expression level of at least one miRNA gene product in a peripheral blood... Agent: Istituto Nazionale Di Genetica Molecolare - Ingm

20120238618 - Pharmaceutical composition comprising anti-mirna antisense oligonucleotides: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is... Agent: Santaris Pharma A/s

20120238620 - Tryptophanyl-trna synthetase-derived polypeptides useful for the regulation of angiogenesis: The invention provides an isolated nucleic acid encoding a polypeptide capable of inhibiting angiogenesis or neovascularization, wherein the nucleic acid comprises a first polynucleotide sequence comprising a coding sequence at least 95 percent identical to a sequence selected from the group consisting of a polynucleotide SEQ ID NO:6, a polynucleotide... Agent: The Scripps Research Institute

20120238520 - Novel medical use: e

20120238522 - Carotenoid-containing compositions and methods: The present invention is directed to carotenoid compositions and methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administration of an effective amount of astaxanthin and beta-carotene.... Agent:

20120238521 - Compositions and methods for the treatment of musculoskeletal related diseases and disorders using metal ion-citrate analog complexes: e

20120238523 - Glycosaminoglycan mixtures: The present invention relates to osteoblast derived glycosaminoglycan mixtures and to their use in one or more of: inhibition of osteoclastogenesis, enhancement of proliferation of osteoblasts, and/or the treatment or prevention of bone fracture or bone deterioration.... Agent: Agency For Science, Technology And Research

20120238524 - Water-soluble polysaccharide ethers and their use: The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40000 to 50000 g/mole, zero shear viscosity of more than 10 Pas, and pseudoplasticity of more than 20, obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by... Agent: Pharmpur Gmbh

20120238525 - Peritoneal dialysis solutions comprising glucose polymers: Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis... Agent: Baxter International Inc.

20120238526 - Aconitine compounds, compositions, uses, and preparation thereof: Compound derivatives of aconitine are provided, in particular derivatives that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. The subject compounds are useful in treatments, including treatments to modulate neuronal activity or to bring about muscular relaxation.... Agent:

20120238527 - Organophosphorus derivatives and use thereof as uncoupling agents: The invention also relates to a method for preparing same, and to a method for controlling the growth of bacterial biomass in an aqueous system, including adding to said aqueous system or contacting said aqueous system with an efficient amount of an uncoupling agent selected from an organophosphonium derivative as... Agent: Rhodia Operations

20120238528 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent:

20120238529 - Triptolide prodrugs: The invention provides compounds of formula (I): or a salt thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using the compounds of formula I.... Agent: Regents Of The University Of Minnesota

20120238530 - Fatty acid acetylated salicylates and their uses: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20120238531 - Isoxazolidine derivatives: Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.... Agent: Chiesi Farmaceutici S.p.a.

20120238532 - Treatment of human osteosarcoma: The present invention describes the combination of cucurbitacin (CuB) with methotrexate (MTX) for the treatment of cancers, including osteosarcoma. It was discovered that CuB and MTX have synergistic activity against osteosarcoma, which reduces toxicities associated with both chemotherapeutic agents. The present invention also describes the use of CuB for the... Agent: Cedars-sinai Medical Center

20120238533 - (heteroarylmethyl) thiohydantoins as anticancer drugs: The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone... Agent: Bayer Pharma Aktiengesellschaft

20120238534 - Oral suspension of prednisolone acetate: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.... Agent: Taro Pharmaceutical North America, Inc.

20120238536 - Method for treating retinal conditions using an intraocular tamponade: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5;... Agent: Novagali Pharma Sa

20120238535 - Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes: A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with he mouth, such... Agent:

20120238537 - Synthetic bile acid compositions and methods: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.... Agent: Kythera Biopharmaceuticals, Inc.

20120238538 - Macrocyclic amides, pharmaceutical compositions, preparation methods and uses thereof: Macrocyclic amide WH-21091 with antibacterial and antitumor activities, its analogs, preparation methods and uses thereof. The said macrocyclic amides are prepared by microbes of Xenorhabdus and Photorhabdus, or they can be prepared by other living beings through transgenic techniques. The compositions of the said macrocyclic amide and its analogs can... Agent: Yuxi Winhey Bio-tech Co., Ltd.

20120238540 - Amino-pyrimidine compounds as inhibitors of ikk epsilon and/or tbk1: The invention relates to certain amino-pyrimidine compounds that inhibit IKK epsilon and/or TBK1, methods of making such compounds, pharmaceutical compositions comprising such compounds, and the use of these compounds in treating a variety of diseases and disorders.... Agent: Myrexis, Inc.

20120238541 - Pharmaceutical compounds: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.... Agent: Almac Discovery Limited

20120238539 - Novel piperazine analogs as broad-spectrum influenza antivirals: e

20120238542 - Aminopyrazoloquinazolines:

20120238543 - Antiviral compounds: Novel compounds, methods, and compositions for treating various viral infections are described. In some embodiments the novel compounds of the invention are 3-oxo-phenothiazine derivatives; more specific embodiments include 3-oxo-phenothiazine derivatives having substituents at the 1-, 7-, and 9-positions of the phenothiazine parent ring. In other embodiments, the invention provides compositions... Agent: Prosetta Antiviral, Inc.

20120238544 - Thieno- and furo-pyrimidine modulators of the histamine h4 receptor: Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.... Agent:

20120238545 - Tricyclic pyrazol amine derivatives: This invention relates to compounds of Formula (I*) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.... Agent: Merck Serono Sa

20120238546 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the Formula (I): Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of Formula (I).... Agent:

20120238548 - 1,4-oxazepines as bace1 and/or bace2 inhibitors: i

20120238547 - 2, 3, 6 - triamino substituted pyridines as kv7 (kcnq) channel modulators: The present application relates to novel substituted aminopyridine derivatives, to their use in therapy, to pharmaceutical compositions comprising the derivatives, to the use of said derivatives in the manufacture of a medicament, and to therapeutic methods comprising the administration of the derivatives. The present derivatives are useful for treating a... Agent: Neurosearch A/s

20120238549 - Nuclear hormone receptor modulators: e

20120238550 - Compound:

20120238551 - Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands:

20120238552 - Pharmaceutical compositions comprising sorbitan esters: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.... Agent: Alkermes, Inc.

20120238553 - Novel benzodioxolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use: This invention relates to novel benzodioxolyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention... Agent: Neurosearch A/s

20120238555 - Pharmaceutical composition containing irbesartan: This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which... Agent: Teva Pharmaceuticals Usa, Inc.

20120238554 - Salts of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing... Agent:

20120238556 - Crystalline methylthioninium chloride hydrates: Three dihydrate forms B, C and D and a monohydrate form E of methylthioninium chloride are described. Forms B, C, D and E can be prepared under controlled humidity and temperature from methylthioninium chloride with higher water content or conversion of a hydrate. The hydrates can be incorporated in pharmaceutical... Agent: Wista Laboratories Ltd.

20120238557 - Aminothiazine or aminooxazine derivative having amino linker: The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R1, R2a, R2b, R3, R4, R5, X, L1, L2, A, ring B and the dotted line are defined in the specification,... Agent: Shionogi & Co., Ltd.

20120238558 - Kinase inhibitors: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the... Agent:

20120238559 - Novel compounds: e

20120238560 - Oxazine derivatives and their use in the treatment of neurological disorders:

20120238561 - Morpholinothiazoles as alpha 7 positive allosteric modulators: The present invention relates to morpholinothiazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulators having the capability to increase the efficacy of nicotinic... Agent:

20120238562 - Treatment of cancer by targeting molecules that influence mst1/stk4 signaling: The invention relates to the treatment of prostate cancer. In various embodiments, the invention teaches a method of administering one or more compounds that inhibit a molecule that antagonizes the activity of tumor suppressor Mst1 and Mst2 pathway signaling. In certain embodiments, one or more of the compounds include an... Agent: Cedars-sinai Medical Center

20120238563 - Novel unsaturated tetracyclic tetrahydrofuran derivatives: e

20120238564 - Imidazo pyrazines:

20120238565 - Triazolopyridine compounds and their use as ask inhibitors: The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation.... Agent: Merck Serono Sa

20120238567 - 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands: The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to some 4, 5, 6, 7 tetrahydrobenzo[b]thiophene derivatives, wherein n is selected from 0, 1, 2, 3 or 4; m is selected from 0, 1 or 2; the dotted line represents either a... Agent: Laboratorios Del Dr. Esteve, S.a.

20120238566 - Use of cell autophagy (type ii cell apoptosis) inhibitors: Use of cell autophagy (type II cell apoptosis) inhibitors for preventing and/or treating avian influenza, injury of lungs caused by avian influenza virus or nanometer materials. The cell autophagy (type II cell apoptosis) inhibitors are selected from 3-methyladenine, SB203580, LY294002, and or wortmannin. The injury of lungs includes acute respiratory... Agent:

20120238568 - Pyrido[2,3-b]pyrazin-8-substituted compounds and their use: The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of... Agent: Cancer Research Technology Limited

20120238571 - Indazole derivatives as pi 3-kinase: e

20120238570 - Inhibitors of the hedgehog pathway:

20120238569 - Thiazole and thiophene compounds:

20120238573 - Prodrugs of [4 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof:

20120238572 - Use of substituted quinazoline compounds in treating angiogenesis-related diseases:

20120238574 - (1, 1, 1,3,3,3 -hexafluoro-2 hydroxypropan- 2 -yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis: The present invention relates to (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives having the general formula (I) to pharmaceutical compositions comprising the same and to the use of these (1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)phenyl derivatives in the treatment of atherosclerosis.... Agent: N.v. Organon

20120238575 - Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones: The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease.... Agent: Merck Serono Sa

20120238577 - Prostaglandin transporter inhibitors and uses thereof: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20120238576 - Triazine derivatives and their therapeutical applications: The present invention comprises inter alia compounds as shown in formula (I) or a pharmaceutically acceptable salt thereof.... Agent: California Capital Equity, LLC

20120238578 - Compositions useful as inhibitors of voltage-gated sodium channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120238580 - Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine: A novel maleate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.... Agent: Sunovion Pharmaceuticals Inc.

20120238579 - New compounds 806: The present invention relates to new compounds of formula (I) and to pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof.... Agent:

20120238581 - Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme: e

20120238582 - Quinazoline derivatives: Novel quinazolinamide derivatives of the formula (I), in which R1-R4 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120238583 - Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the... Agent: Bristol-myers Squibb Company

20120238584 - 5-ht1a receptor subtype agonist: i

20120238585 - Fatty acid acetylated salicylates and their uses: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20120238586 - Fatty acid acetylated salicylates and their uses: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20120238588 - 1h-pyrrolo[2,3-b]pyridines: Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.... Agent: Glaxosmithkline, LLC

20120238587 - Novel pyridopyrimidine derivatives and use thereof: The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases,... Agent: Chemizon, A Division Of Optomagic Co., Ltd.

20120238589 - Organic compounds: 1- or 2-substituted (6aR,9aS)-3-(phenylamino)-5-6a,7,8,9,9a-hexahydro-5-methyl-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(1H or, 2H)-one compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.... Agent:

20120238590 - Compositions for treating cancer-related fatigue and methods of screening thereof: An animal model has been developed based the understanding that a central mechanism in patients with CTRF is that chemotherapy and/or radiation initiates canonical pathways leading to the development of disrupted sleep architecture, resulting in disruption of REM sleep and fatigue and cognitive dysfunction. Drugs that restore the activity patterns... Agent: Tenera Therapeutics, LLC Delaware

20120238591 - Acyclovir formulations: The present invention relates to acyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.... Agent: Emisphere Technologies, Inc.

20120238592 - Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocylcial guanidine: Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for the treatment of facial wrinkling are provided.... Agent: Phytotox S.a.

20120238593 - Heterocyclic compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Avila Therapeutics, Inc.

20120238594 - Azaspirodecanone compounds: e

20120238595 - Therapeutic compounds: The invention provides compounds of formula (I) wherein u, d, v, m, n, R1, W, X, Y, and Z have any values defined herein, as well as salts thereof. The compounds have activity as anti-proliferative agents.... Agent: Rutgers, The State University Of New Jersey

20120238596 - Formulations comprising palonosetron: Pharmaceutical compositions comprising palonosetron and its pharmaceutically acceptable salts, in the form of a ready-to-use solution or a lyophilized form. Specific embodiments of the invention relate to stable pharmaceutical formulations of palonosetron and its pharmaceutically acceptable salts, wherein the formulation does not comprise a chelating agent or an antioxidant.... Agent: Dr. Reddy's Laboratories Limited

20120238598 - Derivatives of 7 alkynyl-1,8 naphthyridones, preparation method thereof and use of same in therapeutics: a

20120238597 - Inhibiting eph b-3 kinase: EphB3 kinase inhibitor compounds, including certain pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine compounds, inhibit EphB3 kinase. The EphB3 kinase inhibitor compounds can have greater potency for the inhibition of EphB3 kinase than general kinase inhibitors. Pharmaceutical compositions, such as neuroprotective agents, comprising the EphB3 kinase inhibitor compounds are also provided. The EphB3 kinase... Agent: Brigham & Women's Hospital, Inc.

20120238599 - Heterocyclic compounds as mek inhibitors: The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory... Agent: Chemizon, A Division Of Optomagic Co., Ltd.

20120238600 - Tropinone benzylamines as beta-tryptase inhibitors: e

20120238601 - Treatment of cancer: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.... Agent: Bipar Sciences, Inc.

20120238602 - Piperidine sulphonamide derivatives: wherein Ar1, Ar2, R1, R2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula I are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag... Agent:

20120238603 - Treatment for inflammatory bowel disease: e

20120238604 - Cytotoxic compounds: The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt or solvate or thereof. In particular, the present invention relates to a method treating diseases involving cell proliferation, migration, apoptosis, or adhesion, comprising administering to a human or non-human mammalian patient an effective amount... Agent: Molecular Discovery Systems

20120238605 - Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients: The invention relates to the use of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in non-ST elevation myocardial infarction, said treatment comprising administering a therapeutically effective amount of (2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof to... Agent: Sanofi

20120238606 - Azilsartan organic amine salts, preparation method and use thereof: Azilsartan amine salts, their preparation and method of use are disclosed. Specifically, azilsartan amine salts represented by formula (I), their preparation, pharmaceutical compositions containing a therapeutically effective amount of the compounds and their use for treating hypertension are disclosed.... Agent: Jiangsu Hans Pharmaceutial Group Co., Ltd.

20120238607 - Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof: The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or... Agent: Bayer Pharma Aktiengesellschaft

20120238608 - Angiotensin ii receptor antagonists: A compound having the structure wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) —C(R1R2) (C(R3R4))0-1Y1R5, and 3) —C(R1R2)—O—Y1R5; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is; Y1 is selected from the... Agent: Merck Sharp & Dohme

20120238609 - Methods for treating copd: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for treating COPD.... Agent: The Board Of Regents Of The University Of Texas System

20120238610 - Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression: Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment... Agent:

20120238611 - Dual-acting benzoimidazole antihypertensive agents: wherein Ar, r, n, X, R2, R2′, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a... Agent: Theravance, Inc.

20120238612 - Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof: New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia.... Agent: Pliva Hrvatska D.o.o.

20120238613 - Sec-hydroxycyclohexyl derivatives: w

20120238614 - Anticonvulsant combination therapy: The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures.... Agent: Ucb Pharma Gmbh

20120238615 - Alpha adrenergic receptor modulators: Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor, in particular the alpha 2C receptor. The compounds can include N-(2,3-substituted phenyl)-3,4-dihydro-2H-pyrrol-5-amine derivatives. Methods of making, using and formulating these compounds are described... Agent: Allergan, Inc.

20120238616 - Methods and compositions for treating sleep-related breathing disorders: Provided herein are methods of treating a sleep-related breathing disorder, such as obstructive sleep apnea, comprising the administration of O-desmethylvenlafaxine or duloxetine.... Agent:

20120238621 - Oligomer-calcimimetic conjugates and related compounds: The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.... Agent: Nektar Therapeutics

20120238622 - Iron (iii) citrate, substantially free of beta-iron hydroxide oxide: This invention provides a method for producing high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, and medical uses thereof.... Agent: Japan Tobacco Inc.

20120238623 - Inflammation and autoimmune disorder treatment using rara selective agonists: The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection.... Agent:

20120238624 - Formulations for the treatment of pain: Formulations and methods are provided for the treatment of pain, and neuropathic pain in particular. The formulations are eutectic mixtures of a capsaicinoid and a local anesthetic agent and/or an anti-pruritic agent.... Agent:

20120238625 - Biologically active oils: A process for the production of fats or oils and their extracts containing biologically active chemical compounds from a lipid substrate, the process comprising: a) inoculation of a lipid substrate with fungally derived lipolytic enzymes; b) incubating the inoculated substrate for a period of between about 7-120 days at a... Agent:

20120238626 - Methods and compositions for promoting the respiratory development of an infant: The present invention relates to methods for promoting respiratory development, reducing the incidence of respiratory distress, bronchopulmonary dysplasia and/or hayfever in an infant by administration of fatty acids and compositions comprising same, wherein the fatty acids are enriched with respect to docosahexaenoic acid (DHA) content.... Agent: Women's & Children's Health Research Institute

20120238627 - N-acetyl-l-cysteine for the treatment of endometriosis: The invention relates to a new prescription of NAC in the treatment of endometriosis and of indications associated with endometriosis, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the... Agent: Iasomai Ab

20120238628 - Dihydronaphthalene and naphthalene derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators: The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.... Agent:

20120238629 - Addition compounds of guanidinoacetic acid: The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and... Agent:

20120238630 - Compositions comprising nonsteroidal anti - inflammatory drugs: The present invention describes liquid compositions comprising pharmaceutically active principles, like scarcely water-soluble, nonsteroidal anti-inflammatory drugs, in particular, but not exclusively, flurbiprofen (FP), processes for their manufacture and their therapeutic use. The liquid compositions comprising FP in association with natural polymers, like xyloglucans (XG), and pharmaceutically acceptable excipients like glycerol,... Agent: Alfa Wassermann S.p.a.

20120238631 - Compositions comprising cyclohexylamines and aminoadamantanes: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations,... Agent: Merz Pharma Gmbh & Co. Kgaa

20120238632 - Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or... Agent: Revision Therapeutics, Inc.

20120238633 - Hypotensive lipid-containing biodegradable intraocular implants and related methods: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.... Agent: Allergan, Inc.

20120238634 - Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the... Agent: Nereus Pharmaceuticals, Inc.

20120238635 - Antiseptic solution of di(4-chloro-phenyldiguanido) compound and process therefor: The present invention relates to a stable antiseptic solution comprising: a di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof, wherein said di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to a process for preparing... Agent: Combino Pharm, S.l.

20120238636 - Rasagiline orally disintegrating compositions: This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant,... Agent:

20120238637 - Isolated extract of walnuts, method for its obtention and its use: The invention refers to an isolated extract of walnuts of high efficiency and stability over time useful for the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases, which is characterized in that it is obtained from a process comprising: i) collecting unripe walnut fruits as... Agent: Hartington Business, S.l.

20120238638 - Biological biocide additives for polymers: This invention pertains to a method of modifying biocides obtained from biological sources, namely polyphenols. The modified biocide may have protective groups to reduce or prevent the oxidation of these phenols. The protective groups may also control the rate of hydrolyzation with regards to biocide efficacy. This invention also includes... Agent:

20120238639 - Pharmaceutical composition comprising propofol: The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as... Agent: Novaliq Gmbh

20120238641 - Dendritic polyurea for solubilizing active substances of low solubility: The present invention provides a composition comprising an amphiphile and an active ingredient whose solubility in water at 20° C. is not more than 10 g/L, wherein the amphiphile comprises a dendritic polyurea which is joined to at least one linear or comb-type polymer, and the joining is effected via... Agent: Basf Se

20120238640 - Polymer derivatives comprising an imide branching point: The invention provides a water-soluble polymer comprising (i) an imide group comprising a linking nitrogen atom, a first carbonyl group covalently attached to the linking nitrogen atom, and a second carbonyl group covalently attached to the linking nitrogen atom; (ii) a first water-soluble polymer segment covalently attached, either directly or... Agent:

20120238642 - Polymer mechanical damping composites and methods of production: A method of reshaping an article comprising a polyelectrolyte complex, the polyelectrolyte complex comprising an intermolecular blend of a predominantly positively-charged polyelectrolyte and a predominantly negatively charged polyelectrolyte by controlling the salt doping level.... Agent: Florida State University Research Foundation, Inc.

20120238643 - Inactivation of off-taste inducing enzymes: The present inventions relates to a method for the production of gellan gum, under mixing conditions, the method comprising a) providing a fermentation broth or other liquid medium containing gellan gum, b) if necessary adjusting the temperature and the pH of the fermentation broth/liquid medium to allow or facilitate enzymatic... Agent: Danisco A/s

20120238644 - Fragmented hydrogels: Fragmented polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.... Agent:

  
09/13/2012 > 178 patent applications in 138 patent subcategories. class, title,number

20120231993 - New synthetic route for the preparation of alpha-amino boronic acid derivatives via substituted alk-1-ynes: The present invention relates in general to the field of organic chemistry and in particular to the preparation of α-amino boronic acid derivatives.... Agent: Lek Pharmaceuticals D.d.

20120231994 - Antagonism of human formyl peptide receptor for treatment of disease: The present invention is directed to modulators of eosinophilic and neutrophilic function and the use of such modulators for treatment of eosinophil-associated and neutrophil-associated diseases.... Agent: Nikan Pharmaceuticals, LLC

20120231995 - Use of pyrroloquinoline compounds to kill clinically latent microorganisms: e

20120231996 - Phalloidin derivatives and methods for their synthesis: The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of Amanita sp. poisoning.... Agent:

20120231997 - Recombinant human cc10 protein for treatment of influenza: Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, to reduce virus titers in the tissues of patients, particularly influenza titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza infection. More... Agent: Clarassance, Inc.

20120231998 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent:

20120231999 - Peptidic glp-2 agonists: Novel GLP-2 analogs with improved pharmacokinetic properties are described as well as their use in the treatment of disease.... Agent: Ferring B.v.

20120232000 - Methods and compositions for promoting regeneration by increasing intracellular sodium concentration: The invention provides methods and compositions for increasing the intracellular sodium concentration in a cell.... Agent: Tufts University

20120232001 - Stable formulations for parenteral injection of peptide drugs: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.... Agent: Xeris Pharmaceuticals, Inc.

20120232002 - Slow-acting insulin preparations: a

20120232003 - Compositions and methods for diabetes treatment: The present invention relates to methods and compositions for the treatment or prevention of type 2 diabetes by administering an effective amount of a melatonin receptor agonist to a human subject in need of such treatment or prevention.... Agent:

20120232004 - Methods for treating autoimmune disorders, and reagents related thereto: The invention generally relates to improved methods for the treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease.... Agent: Trustees Of Tufts College

20120232005 - Lipoprotein complexes and manufacturing and uses thereof: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.... Agent: Cerenis Therapeutics Holding S.a.

20120232006 - Production of polyurethane foams: The invention relates to a process for producing polyurethane foams, by frothing and drying mixtures of specific polyurethane dispersions and crosslinkers.... Agent: Bayer Materialscience Ag

20120232007 - Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens: Methods for producing proteins and glycoproteins in Pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant Pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an N-glycan or O-glycan and... Agent: Merck Sharp & Dohme Corp

20120232008 - Plgf-1 in homodimeric form: The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it.... Agent:

20120232009 - Methods for treatment of insulin-like growth factor-1 deficiency: The present invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in... Agent:

20120232010 - Compositions and methods for treating bladder cancer: The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the... Agent: The Regents Of The University Of Colorado, A Body Corporate

20120232011 - Use of rapamycin and rapamycin derivatives for the treatment of bone loss: The present invention relates to a new use of rapamycin and rapamycin derivatives.... Agent:

20120232012 - Compositions having antiangiogenic activity and uses thereof: The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators... Agent: The Johns Hopkins University

20120232013 - Cross-linked gelatin composition comprising a wetting agent: Disclosed is a biocompatible, hemostatic, cross-linked gelatin composition comprising a biocompatible material comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the sponge in the presence of an aqueous solution.... Agent: Boston Scientific Scimed, Inc.

20120232014 - Antithrombotic compounds: A soluble compound for preventing or reducing blood coagulation comprising an antithrombotic agent and a membrane binding element, wherein the antithrombotic agent has a weight of less than about 5,000 daltons. Also disclosed is a soluble compound for preventing or reducing blood coagulation comprising an anticoagulant joined to a membrane... Agent: King's College London

20120232015 - Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents: A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula Ia, or more particularly Formula Ib, or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of... Agent:

20120232016 - Method and system to detect and diagnose alzheimer's disease: Various embodiments provide methods for the detection, the diagnosis, and/or the prediction of disease onset of Alzheimer's disease. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate, labeling the... Agent:

20120232017 - Reduced volume formulation of glatiramer acetate and methods of administration: A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RAMS) comprising administering to the patient 0.5 ml of an aqueous pharmaceutical solution of 20 mg glatiramer acetate and 20 mg mannitol and an injection assisting device for facilitating the administration of the pharmaceutical... Agent:

20120232018 - Polycarbonates for delivery of drugs and methods of preparation thereof: wherein i) t and t′ are integers independently having a value from 0 to 6 wherein t′ and t cannot both be zero, ii) each Q1 is a monovalent radical independently selected from the group consisting of hydrogen, halides, alkyl groups comprising 1 to 30 carbons, and aryl groups comprising... Agent: International Business Machines Corporation

20120232019 - Compositions and methods for treatment of eye disorders: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.

20120232020 - Method of improving transplant function using soluble complement receptor type i (scr1): A method is disclosed for inhibiting complement activation in brain-dead organ donors, particularly kidney donors, which leads to improvement of organ function of transplanted organs in recipients. The method involves administration of a complement inhibitory protein, specifically a soluble complement receptor type I (sCR1) polypeptide to the donor prior to... Agent:

20120232022 - Botulinum toxin treatments: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan Inc.

20120232021 - Peptide linkers for polypeptide compositions and methods for using same: Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in... Agent:

20120232024 - Therapeutic uses of soluble alpha-klotho: The present invention relates to therapeutic uses of soluble alpha-Klotho.... Agent: Eli Lilly And Company

20120232023 - Whey protein product and a method for its preparation: The invention relates to a whey protein product having a ratio of whey protein to casein in the range from about 90:10 to about 50:50 and the total protein content of at least 20% on dry matter basis, and a method for its preparation. The product has a favourable amino... Agent:

20120232025 - Safener drug combinations for use with nmda antagonist drugs: Prolonged administration of subanesthetic dosages of ketamine, which suppresses activity at NMDA receptors, can provide a damaged central nervous system with an opportunity to use its innate healing processes to “reset” NMDA receptors which were pushed into an unwanted hyper-sensitized state by unusually high activity. However, such treatments can cause... Agent:

20120232026 - Spirocyclic isoxazoline derivatives as antiparasitic agents: o

20120232027 - Crosslinking branched molecule through thiol-disulfide exchange to form hydrogel: In a process for forming a hydrogel, a precursor crosslinkable through disulfide bonds for forming the hydrogel is provided in a solution. The precursor comprises a branched molecular structure, which comprises a plurality of branches. At least three of the branches each comprises a disulfide bond. The pH in the... Agent: Agency For Science Technology And Research

20120232124 - Compositions and methods for prognosis and treatment of prostate cancer: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.... Agent: Rosetta Genomics Lts

20120232125 - Modulation of diacylglycerol acyltransferase 1 expression: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 1. Methods of using these compounds for modulation of diacylglycerol acyltransferase 1 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol... Agent: Isis Pharmaceuticals, Inc.

20120232126 - Multi-targets interfering rna molecules and their applications: This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has... Agent: Biomics Biotechnologies Co., Ltd

20120232127 - Regulation of neurotransmitter release through anion channels: A novel use of anion channels, preferably Ca2+-activated anion channels (CAACs), in regulating release of neurotransmitters from neurons and/or astrocytes is provided. More specifically, CAAC activity regulators, agents for regulating neurotransmitter release comprising such CAAC activity regulators, and methods of screening agents for regulating neurotransmitter release using CAAC as a... Agent: Korea Institute Of Science And Technology

20120232128 - Treatment of influenza: The present invention provides a double-stranded RNA which inhibits replication of influenza B viruses by RNA interference, in which the double-stranded RNA comprises an RNA having 19 to 25 nucleotides homologous with a part of an mRNA transcribed from a genomic RNA of the influenza B viruses and an antisense... Agent: Kyorin Pharmaceutical Co., Ltd.

20120232133 - Delivery of proteins using adeno-associated virus (aav) vectors: Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors.... Agent: California Institute Of Technology

20120232131 - Gene expression and pain: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.... Agent: Adynxx, Inc.

20120232130 - Methods for inhibiting starvation of a cell: The present invention is directed to methods for the treatment or prevention of starvation in a cell, e.g., a neuronal cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which enhances the intracellular generation and/or uptake... Agent:

20120232129 - Multiantivirus compound, composition and method for treatment of virus diseases: A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate... Agent: Biocell Laboratories

20120232132 - Rna antagonists targeting gli2 for the treatment of leukemia: The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.... Agent:

20120232028 - Bicyclic compound, production and use thereof: wherein, R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent... Agent: Tobira Therapeutics, Inc.

20120232029 - 2',4'-substituted nucleosides as antiviral agents: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2′,4′-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.... Agent: Pharmasset, Inc.

20120232030 - Heat stable hyaluronic acid compositions for dermatological use: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.... Agent: Allergan, Inc.

20120232031 - Injectable formulations for intra-articular or peri-articular administration: Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for intra-articular or peri-articular administration disclosed herein comprises a therapeutically-effective amount of a leukotriene synthesis inhibitor compound formulated for intra-articular or peri-articular administration.... Agent: Panmira Pharmaceuticals, LLC

20120232032 - Antimicrobial and/or epithelial cell growth stimulating substance and composition and tissue dressing material: A chitosan for use in an antimicrobial treatment of a patient's tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patient's tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of... Agent: Medovent Gmbh

20120232033 - Amines or amino alcohols as glyt1 inhibitors: c

20120232034 - Vesicular formulations: Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation... Agent:

20120232035 - Bicyclic pyrimidinones and uses thereof: The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a... Agent: Avexa Limited

20120232036 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.... Agent: Rigel Pharmaceuticals, Inc.

20120232037 - Treatment of obesity, metabolic syndrome, and diabetes with protein kinase c inhibitors: Disclosed herein are methods for treating obesity, metabolic syndrome, diabetes, or a combination of these conditions. The methods include selecting a subject with obesity, metabolic syndrome, or diabetes and administering to the subject a therapeutically effective amount of a composition comprising a compound that specifically inhibits hepatic protein kinase C... Agent: The United States Government As Represented By The Department Of Veterans Affairs

20120232038 - Crystalline forms of (3r, 3as, 6ar) - hexahydrofuro [2,3-b] furan-3-yl (1s,2r) - (1-{4-[ (diethoxyphosphoryl) methoxy] pheny1}-3-hydroxy-4- [4-methoxy-n- (2-methylpropyl) benzenesul - fonamido] butan-2-yl) carbamate: The present inventions provides crystalline forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-(1-{4-[(diethoxyphosphoryl)methoxy]phenyl}-3-hydroxy-4-[4-methoxy-N-(2-methylpropyl)benzenesulfonamido]butan-2-yl)carbamate, methods of preparing the crystalline forms, pharmaceutical compositions containing the crystalline forms, and therapeutic uses thereof.... Agent: Gilead Sciences, Inc.

20120232039 - Primary amine diazeniumdiolate heterocyclic derivatives: e

20120232040 - Medication for clinical extensively-drug resistant acinetobacter baumannii: A medication for Acinetobacter baumannii infection comprises tetracycline; and a ginger compound, selecting from a group of [6]-dehydrogingerdione, [10]-gingerol, [6]-shogaol and [6]-gingerol. Also, a method for improving tetracycline-resistance of A. baumannii, by providing the ginger compound described above combined with tetracycline to against A. baumannii infection.... Agent:

20120232041 - Pharmaceutical composition for treating or preventing angina or myocardial infarction induced by myocardial ischemia: The present invention provides a pharmaceutical composition for the treatment and prophylaxis of angina and myocardial infarction, wherein a combination of a tea extract (catechins) and an antianginal drug are proved therapeutically potent in treating angina and mycocardial infarction induced from myocardial ischemia. The present invention also provides a use... Agent: Sinphar Tian-lipharmaceutical Co., Ltd. (hangzhou)

20120232042 - 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases: The invention relates to 17-hydroxy-13-methyl-17-pentafluoroethyl-11-acyloxyalkylenephenyldodecahydrocyclopenta[a]phenanthren-3-one derivatives of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas,... Agent: Bayer Pharma Aktiengesellschaft

20120232043 - Lubiprostone for obstetrical or gynecological applications: The invention relates to a method for terminating pregnancy or for menstrual induction, which method comprises administering a female subject with lubiprostone, preferably in combination of a progesterone receptor antagonist, such as mifepristone.... Agent: Cemag

20120232044 - Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia: Methods and compositions for treating and/or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.... Agent: Twi Biotechnology, Inc.

20120232045 - Methods and systems for prognosis of a patient's response to treatment of androgenetic skin disorders: Methods and systems are described for prediction of a patient's response to a drug for treating androgenetic skin disorders such as alopecia, acne, and hirsutism. For a given drug such as anti-androgens and 5-alpha-reductase inhibitors, and a given dosage, the likely responsiveness of that drug and dosage may be determined,... Agent:

20120232046 - Method and kit for reducing the symptoms of peripheral vascular disease: A method for reducing the symptoms of peripheral vascular disease and for improving peripheral circulation wherein a progestin is administered to a subject in need thereof.... Agent: Dimera Incorporated

20120232047 - Substituted clavulanic acid: m

20120232048 - Method for modulating gpr119 g protein-coupled receptor and selected compounds: A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent.... Agent: Bristol-myers Squibb Company

20120232051 - 3-amino-pyridines as gpbar1 agonists: m

20120232052 - Aryl carboxamide derivatives as ttx-s blockers: The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO2—, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels,... Agent:

20120232050 - Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (III). (III-A). (IIII-B). (III-C). (III-D), (III-E) (IV), (IV-A), (IV-B). (IV-C), (IV-D). (V), (V-A), (V-B), (V-C), (V-D), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with... Agent: Vitae Pharmaceuticals, Inc.

20120232049 - Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene: wherein R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to... Agent: Eisai R&d Management Co., Ltd.

20120232053 - Quaternary ammonium compounds useful as muscarinic receptor antagonists: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a, Z and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to,... Agent: Theravance, Inc.

20120232056 - Heterocyclic compounds for the inhibition of pask: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.... Agent: Bioenergenix

20120232055 - Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors: s

20120232054 - Pyrrolotriazine compounds: wherein all symbols have the same meanings as defined in the specification; a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, has a Btk inhibitory activity, and is useful as a method for preventing and/or treating a rheumatoid arthritis, an autoimmune disease, a B cell lymphoma... Agent: Locus Pharmaceuticals, Inc.

20120232057 - Chiral fused [1,2]imidazo[4,5-c] ring compounds: Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X1—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in... Agent: 3m Innovative Properties Company

20120232058 - Substituted pyridine derivatives and their medical use: The present application relates to novel substituted pyridine derivatives, to their use in therapy, to pharmaceutical compositions comprising the derivatives, to the use of said derivatives in the manufacture of a medicament, and to therapeutic methods comprising the administration of the derivatives. The present derivatives are useful for treating a... Agent: Neurosearch A/s

20120232059 - Modulators of atp-binding cassette transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Incorporated

20120232060 - Modified release preparations containing oxcarbazepine and derivatives thereof: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.... Agent: Supernus Pharmaceuticals, Inc.

20120232061 - Novel compounds: which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory diseases and/or allergic conditions, in cancer therapy, specifically heme malignancies, and autoimmune conditions.... Agent: Glaxo Group Limited

20120232062 - Azaindazoles to treat flaviviridae virus infection: Azaindazole compounds are useful for treating Flaviviridae virus infection, including HCV infection.... Agent: Eiger Biopharmaceuticals, Inc.

20120232063 - 2-aminoindole compounds and methods for the treatment of malaria: The present invention relates to methods of treating a subject with malaria comprising administering a 2-aminoindole compound represented by Formula: (I)—The values and preferred values of the variables in Structural Formula I are defined herein.... Agent:

20120232064 - Aspartyl protease inhibitors: Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or... Agent: Schering Corporation

20120232066 - Compositions for reducing risk of adverse events caused by drug-drug interactions: The present disclosure provides a composition comprising a GABAA agonist and a GI enzyme inhibitor. The present disclosure also provides a composition comprising (a) a GI enzyme inhibitor and (b) a first drug that interacts with a second drug to produce an adverse effect when the second drug is co-ingested... Agent:

20120232065 - Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them: e

20120232067 - Benzodiazepinone compounds and methods of treatment using same: The invention provides 1,4-benzodiazepinone compounds, pharmaceutical compositions, and methods of treating autoimmune disorders, chronic inflammatory disorders, and hyperproliferative disorders. For example, the 1,4-benzodiazepinone compounds and pharmaceutical compositions are contemplated to be useful for treating rheumatoid arthritis, graft-versus-host disease, inflammatory bowel disease, and the like.... Agent: The Regents Of The University Of Michigan

20120232068 - Quinazolines as potassium ion channel inhibitors: A compound of formula (I) wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur associated disorders, and other disorders mediated by ion channel function.... Agent: Briston-myers Squibb Company

20120232071 - 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds: wherein R1a to R1e, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as... Agent:

20120232073 - Fused bicyclic pyrimidine derivatives and methods of use thereof: The present invention relates to Fused Bicyclic Pyrimidine Derivatives, compositions comprising a Fused Bicyclic Pyrimidine Derivative, and methods of using the Fused Bicyclic Pyrimidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR)... Agent:

20120232072 - Imidazopyridine derivatives: wherein Ra, Rb, Rc, Rd, Re and Rf are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR), Signal transducer and activator of transcription 3 (STAT 3), tumor necrosis... Agent: Piramal Life Sciences Limited

20120232069 - Process for preparing efavirenz polymorph: The present invention relates to a process for the preparation of crystalline non-hygroscopic form H1 of efavirenz, and pharmaceutical compositions containing it. In accordance with the present invention efavirenz was dissolved in acetone at 25° C.-30° C., the solution was slowly added to water at 0° C.-5° C., the separated... Agent: Hetero Research Foundation

20120232070 - Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease: e

20120232074 - Imidazo [4, 5-c] quinoline derivatives as bromodomain inhibitors:

20120232075 - Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases:

20120232076 - Quinolizidinone carboxamide m1 receptor positive allosteric modulators: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions... Agent:

20120232077 - Selective antibacterials for clostridium difficile infections: The invention features compounds of formula (I): The compounds are useful as antibacterial agents, especially again Clostridium difficile-associated diseases.... Agent:

20120232079 - Novel acylpiperazinones and their use as pharmaceuticals: The invention relates to novel acylpiperazinone compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.... Agent:

20120232078 - Novel medicaments: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system,... Agent: High Point Pharmaceuticals, LLC

20120232080 - Phenoxy acetic acids as ppar delta activators: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-δ and should be useful for treating conditions mediated by the same.... Agent: High Point Pharmaceuticals, LLC

20120232081 - Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals: wherein R, Ra, R10, R20, R30, R40, Y, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension,... Agent: Sanofi

20120232082 - Novel compounds and therapeutic use thereof for protein kinase inhibition: Novel compound having the following formula: (I) wherein Y is N, O, or S. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein... Agent:

20120232083 - Fluoro-pyridinone derivatives useful as antibacterial agents: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.... Agent: Pfizer Inc

20120232084 - Pyrrolidin-3-ylmethyl-amine as orexin antagonists: e

20120232085 - 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them: Compounds which are 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected... Agent: Nerviano Medical Sciences S.r.l.

20120232086 - Fused tricyclic compounds with adenosine a2a receptor antagonist activity: The present invention relates to certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the “Fused Tricyclic Compounds”), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides... Agent: Merck Sharp & Dohme Corp.

20120232087 - Methods and compositions for treating solid tumors and other malignancies: A combination of a kinase inhibitors of mTOR and downstream effector and a hedgehog pathway inhibitor for the treatment of cancer.... Agent:

20120232088 - Piperazinedione compounds: This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.... Agent: Taipei Medical University

20120232090 - Arylpiperazine-containing purine derivatives and uses thereof: A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.... Agent: Green Cross Corporation

20120232089 - Method of treating an anxiety disorder: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other... Agent: Kyowa Hakko Kirin Co., Ltd.

20120232091 - Polymorphic forms of manidipine: The invention relates to various new polymorphic forms of manidipine and pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of the polymorphic forms of manidipine and pharmaceutically acceptable salts thereof.... Agent: Cipla Limited

20120232092 - Heterocyclic sulfonamides: Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Cytokinetics, Inc.

20120232093 - Pyrazole derivatives as sigma receptor inhibitors: r

20120232095 - Benzofuran derivatives:

20120232096 - Benzofuran derivatives:

20120232094 - Use of adrenergic n-phenylpiperazine antagonists, pharmaceutical compositions containing them, and methods of preparing them: which selectively act on the alpha 1A/alpha 1D subtypes, where its selectivity index in comparison to alpha 1B subtype is, at minimum, 1700 for the alpha 1A subtype and 10000 for the alpha 1D subtype, being therefore useful for the treatment of the lower urinary tract symptoms, including the benign... Agent:

20120232097 - Cinnamoyl-piperazine derivatives and their use as par-1 antagonists: i

20120232098 - Methods of predicting and treating adverse cardiac events: The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human... Agent:

20120232099 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20120232100 - Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses: Solid forms comprising 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed... Agent:

20120232101 - Novel compounds: l

20120232102 - Methods of administration and treatment: The present invention is directed to methods of administering pazopanib or pharmaceutically acceptable salts or solvates thereof as well as methods of treating cancer and age-related macular degeneration in patients in need thereof.... Agent:

20120232103 - Novel 5-fluorouracil derivative: e

20120232104 - Novel sulfonamides as l-cpt1 inhibitors:

20120232107 - Non-peptide antagonists of gastrin releasing peptide: This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or... Agent: The Government Of The United States Of America As Represented By The Secretary, Department Of Health

20120232105 - Pharmaceutical composition for inhibiting osteoclast growth: i

20120232106 - Treatment for discoid lupus: Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the skin, such as cutaneous lupus, for example acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, or discoid lupus erythematosus. In certain embodiments, the compounds are provided in topical... Agent: Rigel Pharmaceuticals, Inc.

20120232108 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the Formula I: Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of Formula I.... Agent:

20120232109 - 3-substituted sulfonyl piperidine derivative: wherein n1, n2, and n3 are 0, 1, or 2, respectively; R1 represents C1-6 alkyl, C3-8 cycloalkyl, or the like; R2 represents aryl or heteroaryl; R3 represents a hydrogen atom, C1-6 alkyl, or the like; and M1, M2, M3, and M4 independently represent a hydrogen atom, C1-6 alkyl, or the... Agent:

20120232110 - Antimicrobial compounds: This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in inhibiting the ability of a bacterium to kill a host organism, as well as methods for using these compounds for treating bacterial infections.... Agent: The General Hospital Corporation

20120232111 - Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin: The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin—inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and further provides an external composition for skin to which a compound... Agent: Shiseido Company, Ltd.

20120232112 - Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals: wherein A, D, E, G, R10, R11, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases... Agent: Sanofi

20120232113 - Methods of treating emesis using growth hormone secretagogues: The present invention relates to methods of treating or preventing emesis and improving a subject's ASAS score by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.... Agent: Helsinn Therapeutics (u.s.), Inc.

20120232114 - Compositions containing opioid antagonists: Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having... Agent: Adolor Corporation

20120232115 - Pharmaceutical, dietary supplement, and food grade salts of anatabine: Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment,... Agent: Rock Creek Pharmaceuticals, Inc.

20120232116 - Novel fxr (nr1h4) binding and activity modulating compounds: The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of... Agent: Phenex Pharmaceuticals Ag

20120232117 - Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same: The present invention provides pyrazole derivative compounds and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of preventing and treating osteoporosis.... Agent: Ewha University-industry Collaboration Foundation

20120232118 - Selective ligands for the dopamine 3 (d3) receptor and methods of using the same: e

20120232119 - Method for treating a keratoconjunctival disorder: A method for treating a keratoconjunctival disorder, wherein the keratoconjunctival disorder comprises at least one disorder selected from the group consisting of a superficial punctate keratopathy, a corneal epithelial defect, corneal erosion, a corneal ulcer, a conjunctival epithelial defect, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, keratitis and conjunctivitis, and... Agent: Santen Pharmaceutical Co. Ltd.

20120232120 - Amino acid amides of phenoxybutyric acid derivatives: where X is phenyl substituted at the 3, 4 and 5 positions with R1, R2 or R3 which are selected from hydrogen, chloro, lower alkyl of 1 to 5 carbons, phenoxy, phenyl, naphthyl, or phenyl (lower) alkyl where the lower alkyl group has 1-5 carbon atoms and m is 0... Agent:

20120232121 - Use of sarcoplasmic ca2+-atpase type 2 protein for diagnosing and treating learning or mental disorders: The present invention embraces methods for the diagnosis and treatment of learning or mental disorders, as well as the identification of agents useful in the treatment of such disorders based upon the identified involvement of Sarcoplasmic Ca2+-ATPase type 2 Protein in synaptic plasticity and neurotransmitter release in 22q11 deletion/DiGeorge Syndrome.... Agent: St. Jude Children's Research Hospital

20120232122 - Tricyclic heterocyclic derivatives: The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy,... Agent:

20120232123 - Liquid pharmaceutical compositions: Aqueous liquid pharmaceutical composition comprising a) almotriptan and b) at least one compound selected from i) 1′-methyl-5-((pyrrolidin-1-ylsulfonyl)methyl)spiro[indoline-3,3′-pyrrolidin]-2-ol, and ii) 3-(2-(dimethylamino)ethyl)-5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-2-ol.... Agent:

20120232134 - Combination cancer therapy with bis(thiohydrazide) amide compounds: Disclosed is a method of treating a subject with cancer, the method comprising the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2; and a bis(thiohydrazide amide) compound in an amount between about 1473 μmol/m2... Agent: Synta Pharmaceuticals Corp.

20120232135 - (-)-epigallocatechin gallate derivatives for inhibiting proteasome: A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:... Agent: Wayne State University

20120232136 - Substance with sedative effect: A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose, the substance can be used to treat various... Agent:

20120232137 - Use of bethaneciol for treatment of xerostomia: Bethanechol is administered topically, for the treatment of xerostomia.... Agent:

20120232138 - Amidoacetonitrile compounds having pesticidal activity: Novel amidoacetonitrile compounds and compositions containing the compounds are disclosed. The compounds have pesticidal properties and are suitable for controlling endoparasites on warm-blooded animals.... Agent: Novartis Ag

20120232139 - Composition for ocular topical administration treatment ocular hypertension and glaucoma: The present invention provides a composition for ocular topical administration for treating ocular hypertension and glaucoma, comprising latanoprost as an active ingredient, and (a) a polyol and/or sugar alcohol, (b) a nonionic surface active agent, and (c) an edetic acid compound. The composition of the present invention comprises lower amount... Agent:

20120232140 - Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension: The present invention relates to a pharmaceutical combination comprising a prostaglandin compound and a NSAID. The present invention particularly relates to an ophthalmic composition comprising travoprost and bromfenac for the treatment of glaucoma and ocular hypertension.... Agent: Micro Labs Limited

20120232141 - Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty... Agent:

20120232142 - Novel use of dimethylfumarate: Disclosed are a pharmaceutical composition for inhibiting vascular smooth muscle cell proliferation comprising dimethyl fumarate as an effective ingredient, use of dimethyl fumarate for inhibiting vascular smooth muscle cell proliferation, and a method of inhibiting vascular smooth muscle cell proliferation employing the same. Through the present invention, it was found... Agent: Kyungpook National University Industry Academic Cooperation Foundation

20120232143 - Lipid derivatives: The present invention relates to lipid compounds of the general formula (I): wherein —R1 and R2 are the same or different and may be selected from a group of substituents consisting of a hydrogen atom, an alkyl group, a halogen atom, and an alkoxy group; —X is COR3 or CH2OR4,... Agent: Pronova Biopharma Norge As

20120232144 - Methods of and systems for producing diesel blend stocks: A method for producing biofuels is provided. A method of making biofuels includes dewatering substantially intact algal cells to make an algal biomass, extracting neutral lipids from the algal biomass, and esterifying the neutral lipids with a catalyst in the presence of an alcohol. The method also includes separating a... Agent: Heliae Development, LLC

20120232145 - Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.... Agent: Amarin Pharma, Inc.

20120232146 - Methods of and systems for producing diesel blend stocks: A method for producing biofuels is provided. A method of making biofuels includes dewatering substantially intact algal cells to make an algal biomass, extracting neutral lipids from the algal biomass, and esterifying the neutral lipids with a catalyst in the presence of an alcohol. The method also includes separating a... Agent: Heliae Development, LLC

20120232147 - Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis.... Agent: Dignity Sciences Limited

20120232149 - Solid pharmaceutical compositions containing pregabalin: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.... Agent: Warner-lambert Company LLC

20120232148 - Systems and methods for preventing cancer and treating skin lesions: Systems and methods of using a composition containing at least one or more amino acids for topical application to skin to prevent cancer and treat skin lesions.... Agent:

20120232150 - Phthalanilate compounds and methods of use: The invention provides antimicrobial compounds and compositions, and methods of using them. The compounds and compositions include, for example, a compound of any one of Formulas I-X. The invention further provides methods of preparing the compounds, and useful intermediates for their preparation. The compounds can possess highly specific and selective... Agent: University Of Nortre Dame Du Lac

20120232151 - Process for the preparation of gadobenate dimeglumine complex in a solid form: The present invention discloses a process for the preparation of gadobenate dimeglumine complex in a solid form. In particular, said solid form is conveniently obtained by spray-drying a corresponding liquid suspension at a given temperature and concentration. The present invention is particularly advantageous for the industrial scale as the solid... Agent: Bracco Imaging S.p.a.

20120232152 - Topical ibuprofen formulations: The present application relates to a topical formulation comprising ibuprofen, a hydroalcoholic based solvent system, a C1-4alcohol ester of citric acid, and a surfactant. The formulation shows physical stability over more than one month at ambient temperature and is colourless, essentially odorless, and has a pH value of about 6.5.... Agent: Nuvo Research Inc.

20120232153 - Acidic biofilm remediation: Methods and compositions for biofilm remediation are disclosed. Biofilm is reduced and removed from soiled surfaces by providing to a surface in need an effective amount of a composition comprising a biocidal surfactant and at least one organic solvent. According to the invention, the biofilm remediation compositions reduce and remove... Agent: Ecolab Usa Inc.

20120232154 - Preservatives based on carboxylic anhydrides: Carboxylic anhydrides are highly suitable as additive for industrial materials, cosmetics, pharmaceutics and foodstuffs, in particular beverages, for protecting them against attack and/or destruction by microorganisms.... Agent: Lanxess Deutschland Gmbh

20120232155 - Novel antibacterial hydroxyphenyl compound: The invention relates to a novel hydroxyphenyl compound, to the preparation of the compound and intermediates used therein, to the use of the compound as an antibacterial medicament and pharmaceutical compositions containing the compound.... Agent:

20120232156 - Controlled release dosage forms: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.... Agent: Valeant International(barbados) Srl

20120232157 - Methods of using derivatives of (-)-venlafaxine: Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders,... Agent:

20120232158 - Methods of treating hyperacidic disorders: The present invention relates to methods for treating or preventing hyperacidic disorders such as GERD or NERD using calcium receptor active compounds.... Agent: Amgen Inc

20120232159 - Methods and compositions for treating depression using cyclobenzaprine: The present invention relates to methods for the treatment or prevention of depression, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising cyclobenzaprine, alone, or in combination with an antidepressant drug.... Agent: Tonix Pharmaceuticals, Inc.

20120232160 - Materials and methods for pest control: The present invention provides a novel insecticide formulation that not only demonstrates strong insecticidal and residual activity against a variety of insects, but also exhibits low mammalian toxicity.... Agent:

20120232161 - High alcohol content foaming compositions: This invention relates to a “high lower alcohol content” (>40% v/v of a C1-4 alcohol) liquid composition able to be either dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers or as an alcohol gel composition which does not use thickener and gelling... Agent: Deb Worldwide Healthcare Inc.

20120232162 - Use of lutein containing compositions to improve certain aspects of memory: This invention relates to a method of enhancing an aspect of memory in a healthy individual, wherein the aspect of memory is selected from the group consisting of: associative memory, spatial memory and memory under stress comprising: administering a composition consisting of: a) an effective amount of either lutein or... Agent:

20120232163 - Methods of making olive juice extracts containing reduced solids: Solids, including fibers can be easily removed from olive juice by mixing the olive juice with a water-miscible solvent to form two phases and separating the phases. Preferably the solvent is ethanol.... Agent: DsmIPAssets B.v.

20120232164 - Fibrous calcium pyrophosphate particles and methods of making and using same: Fibrous calcium pyrophosphate particles with a unique fibrous nanostructure are disclosed. The invention includes a composition, comprising fibrous particles, wherein the fibrous particles include fibers and the fibers include calcium and pyrophosphate. Also included are methods for making calcium pyrophosphate particles wherein solutions of calcium salt and pyrophosphate salt are... Agent: Nanunanu Ltd.

20120232165 - Cleaning composition having high self-adhesion and providing residual benefits: A composition for treating a hard surface. The composition has: (a) at least one adhesion promoter; (b) at least one surfactant selected from the group consisting of: anionic, non-ionic, cationic, amphoteric, zwitterionic, and combinations thereof; (c) mineral oil; (d) a blend of linear primary alcohols, wherein each alcohol of said... Agent: S.c. Johnson & Son, Inc.

20120232166 - Masking bitter flavors: Mogrosides may be used as a flavor modifier in various foods, beverages, pharmaceutical compositions, and the like to block the perception of bitter and astringent flavors or other off flavors.... Agent:

20120232167 - Hydroxyalkylcellulose microparticles: Provided is a method of producing hydroxyalkylcellulose microparticles, the method including generating a pulse shock wave, and supplying a hydroxyalkylcellulose aqueous solution to the pulse shock wave generation region, thereby crushing and drying the hydroxyalkylcellulose aqueous solution. According to the production method, hydroxyalkylcellulose microparticles having a volume-average particle size of... Agent: Nippon Soda Co., Ltd.

20120232168 - Liquid concentrate for preserving cosmetics: A liquid concentrate for preserving cosmetic products which includes a combination of carboxylic component being sodium benzoate and an alcohol component being a mixture of phenoxy ethanol and benzyl alcohol, in a water, where the combination is greater than 45% by weight of the liquid concentrate.... Agent: Air Liquide Sante (international)

20120232169 - Highly monodisperse branched peg-lipid conjugates: (PEG)-lipid conjugates and methods of preparation are disclosed herein. Methods of preparation may involve stepwise addition of small PEG oligomers to a glycerol backbone until a desired chain size is attained. Polymers resulting from the syntheses may be highly monodisperse. The resulting polymers may comprise branched polyethyleneglycol (PEG)-lipid conjugates. The... Agent: Biozone Pharmaceuticals, Inc.

20120232170 - Cleaning composition having high self-adhesion and providing residual benefits: A composition for treating a hard surface. The composition has: (a) at least one adhesion promoter; (b) at least one surfactant selected from the group consisting of: anionic, non-ionic, cationic, amphoteric, zwitterionic, and combinations thereof; (c) mineral oil; (d) water; (e) optionally, at least one solvent; and wherein the composition... Agent: S.c. Johnson & Son, Inc.

  
09/06/2012 > 149 patent applications in 113 patent subcategories. class, title,number

20120225807 - Bacterial membrane protein secretion: Improved bacterial secretion signals derived from pelB and ompA are provided. The improved variants enhance bacterial membrane secretion are thus useful for production of proteins secreted from bacteria including proteins displayed on filamentous phage particles, and, in particular, proteins requiring oxidative formation of covalent bonds, such as disulfide bonds within... Agent:

20120225808 - Pharmaceutical composition for preventing / treating trpv1 activity-related and inflammation-related diseases or conditions containing maillard peptide separated from well-aged traditional soy sauce as active ingredient: The present invention relates to a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide according to the present invention functions both as a TRPV1 agonist and a TRPV1... Agent: Korea Food Research Institute

20120225809 - Compounds for treating papilloma virus infection: The present invention relates to polyamide compositions and therapies for treating cells and subjects infected with papilloma virus.... Agent: Nanovir, LLC

20120225810 - Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices: The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to... Agent: Novo Nordisk A/s

20120225811 - Insulin analogues: A dicarba analogue of insulin comprising an A-chain and a B-chain or fragments, salts, solvates, derivatives, isomers or tautomers of the A-chain, the B-chain or both, provided that the dicarba analogue is not [A7,B7-(2,7-diaminosuberoyl]-des-(B26-B30)-insulin B25-amide.... Agent: Monash University

20120225812 - Substituted fused pyrimidine compounds, its preparation and uses thereof: d

20120225813 - Compositions, methods and uses for treatment of type 1 diabetes: Embodiments herein concern compositions and methods for treating diabetes in a subject.... Agent:

20120225814 - Hydrogel-based vascular lineage cell growth media and uses thereof: A medium for growing vascular lineage cells is described. The vascular lineage cell growth medium includes an oligosaccharide-based hydrogel and a growth factor that promotes vascularization by vascular lineage cells.... Agent: The Johns Hopkins University

20120225815 - Novel cellular factor-containing solution compositions: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.... Agent:

20120225816 - Pharmaceutical compositions of melanocortin receptor ligands: The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical... Agent: Ipsen Pharma, S.a.s.

20120225817 - Therapeutic agent for gastrointestinal disease: The present invention provides a therapeutic agent and a prophylactic agent for a gastrointestinal disease. A peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof promotes wound healing in a gastrointestinal mucosal tissue, and is therefore useful as a therapeutic agent or a prophylactic... Agent: Yamaguchi University

20120225818 - Plasma protein effective for suppressing cough: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide... Agent: Ginkyo Academy Kumamoto Health Science University

20120225819 - Stable formulation of factor viii: The invention relates inter alia to a composition which is storage-stable at 25° C. for a minimum of 18 weeks comprising a therapeutically effective amount of Factor VIII and an aqueous medium having a Factor VIII potency after 18 weeks of storage at 25° C. of at least 90% of... Agent:

20120225820 - Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis: Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with rheumatoid arthritis. These novel peptides provide the basis for new methods of diagnosis and... Agent: London Health Sciences Centre Research Inc.

20120225821 - Composition for preventing or treating a spinal cord injury: The present invention relates to a novel use of substance P. The substance P of the present invention exhibits effects of decreasing microglia activity, decreasing proinflammatory cytokines, inhibiting apoptosis, etc. The substance P of the present invention effectively treats degenerative central nervous system diseases or disorders such as a spinal... Agent: University-industry Cooperation Group Of Kyung Hee

20120225822 - Peptides for the treatment of oxidative stress related disorders: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.... Agent: Ramot At Tel-aviv University Ltd.

20120225823 - Allosteric modulation of the dopamine transporter protein for the treatment of hiv-1 induced neurologic dysfunction: A method for increasing dopaminergic neurotransmission in a mammal in need of such treatment is provided. The method comprises disrupting Tat-DAT binding in the mammal.... Agent: University Of South Carolina

20120225824 - Mullerian inhibiting substance (mis) analogues: Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositions comprising such compositions and methods of using such compositions, for example in the treatment of conditions associated with uncontrolled... Agent: The Trustees Of Columbia University In The City Of New York

20120225825 - Cyclodextrin-based polymers for therapeutic delivery: Methods and compositions relating to CDP-taxane conjugates are described herein.... Agent: Cerulean Pharma Inc.

20120225827 - Silicone-based ophthalmic formulations: Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases.... Agent:

20120225826 - Transporters comprising spaced arginine moieties: The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)nZ,... Agent: The Board Of Trustees Of The Leland Stanford Junior University And Cellgate, Inc.

20120225828 - Melanocortin-1 receptor-specific cyclic peptides: e

20120225829 - Method of producing fr901228: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from... Agent: Astellas Pharma Inc.

20120225830 - Method of producing fr901228: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from... Agent: Astellas Pharma Inc.

20120225831 - Melanocortin-1 receptor-specific linear peptides: p

20120225832 - Amphiphilic compositions and methods for preparing and using same: The invention relates to amphiphilic C-glycoside derivatives, to methods of using them and to processes for synthesizing them. Specifically, the invention relates to novel cyclic and linear enone-glycolipids and cyclic ketone-glycolipids.... Agent: Yale University

20120225833 - Composition for treating mental health disorders: A composition of three compounds each selected from a selective re-uptake inhibitor of serotonin, a monoamine oxidase inhibitor, and a phosphodiesterase inhibitor, such that all three compounds are different and are naturally occurring.... Agent: Quercegne Pharmaceuticals LLC

20120225834 - Ocular iontophoresis of charged micelles containing bioactive agents: This invention is related to pharmaceutical compositions consisting of charged micelles containing bioactive agents. The invention is also related to the methods of delivery of charged micelles to the eye of a mammal by iontophoresis.... Agent: Eyegate Pharmaceuticals, Inc.

20120225835 - Antibiotic formulations, unit doses, kits, and methods: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the... Agent:

20120225926 - Amphiphilic macromolecules for nucleic acid delivery: The invention provides amphiphilic macromolecules that are useful for delivering nucleic acids to cells and that are useful as delivery agents for gene therapy.... Agent:

20120225928 - Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to... Agent: Genecare Research Instiute Co., Ltd.

20120225927 - Compositions and methods for inhibiting expression of transthyretin: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.... Agent:

20120225925 - Micro-rna biomarkers and methods of using same: A procedure and an apparatus are described for identifying individuals at risk of pulmonary tumour and/or for diagnosing a pulmonary tumour using the study of levels of expression of miRNA in the blood or another biological fluid. Also described are a method and a compound for reducing or eliminating a... Agent: Biomirna Holdings Ltd.

20120225924 - Single-monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery: A method of synthesizing a random copolymer of polyethyleneimine and polyethylene glycol, comprising exposing ethanolamine in a solution to electromagnetic radiation for a sufficient time to polymerize the ethanolamine (OHCH2CH2NH2) and thereby resulting in formation of the randome copolymer comprising polyethyleneimine and poly(ethylene glycol), wherein the polyethyleneimine comprises ethyleneimine (—CH2CH2NH—)... Agent: National Health Research Institutes

20120225931 - Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods: The present invention relates, inter alia, to methods and compositions for regulating the host response to biomaterials, including inhibiting inflammation from and rejection of biomaterials using salicylate compounds and/or TLR7/TLR9 antagonists as described herein.... Agent: Yale University

20120225930 - Method of treating or retarding the development of blindness: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the... Agent:

20120225929 - Nucleic acid inhibitors of glutamate receptors: The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i.e., SELEX and laser pulse photolysis for the selection and screening of aptamers that... Agent: The Research Foundation Of State University Of New York

20120225932 - Process for the production of polyamines: The present invention relates to a process for the production of a polyamine involving the use of enzymes; in particular to a process performed in aqueous environment; to the polyamines produced by said method; as well as the use of said polyamines for manufacturing paper, for immobilizing enzymes, or for... Agent: Basf Se

20120225933 - Regulated expression systems: The application relates to gene constructs for inducible hepato-specific expression of polynucleotides of interest in response to an inducer agent, said constructs comprising (i) an inducible bi-directional operator-promoter with at least one responsive element to said inducer agent flanked by two hepato-specific promoters acting in divergent manner, (ii) a first... Agent:

20120225838 - Anti-tumor effect potentiator: e

20120225836 - Compositions comprising decitabine and tetrahydrouridine and uses thereof: Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the... Agent: The Board Of Trustees Of The University Of Illinois

20120225837 - Medicinal agent for disease associated with epstein-barr virus, and method for screening of the medicinal agent: 1-(2-Fluoro-4-thio-β-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types... Agent: Yamasa Corporation

20120225839 - Phosphoramidate derivatives of nucleosides: (

20120225840 - Hydroxytyrosol combinations for enhancing mitochondrial function and energy production: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract can be used to maintain or increase mitochondrial biogenesis... Agent:

20120225842 - Hyaluronic acid compositions for dermatological use: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional constituent selected from the group consisting of vitamin B, C and vitamin E, wherein the formulation exhibits greater stability than an HA gel formulation... Agent: Allergan, Inc.

20120225841 - Methods of making and using a ruminant gas reduction composition: A method comprising administering an oligosaccharide composition to an organism having a gastrointestinal system to affect the production of GHG produced by the organism allowing for a reduction of the GHG produced by the organism while optimizing the health, feed intake, and protein synthesis of the organism so that management... Agent: Tin Inc. D/b/a Temple-inland

20120225843 - Use of sulfated glycosaminoglycans for establishing effective labor in women: A method of treating protracted labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerised low molecular weight heparin treated with periodate to eradicate antithrombin III binding affinities, thereby exhibiting an anticoagulant activity of 10 BP units/mg or less and an average molecular... Agent: Dilafor Ab

20120225844 - Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors: In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric... Agent:

20120225845 - Compounds for diseases and disorders: The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH2, -L-C(═O)NH(C1-3 alkyl), -L-C(═O)N(C1-3 alkyl)2, -L-S(═O)2(C1-3alkyl), -L-S(═O)2NH2, -L-S(═O)2N(C1-3 alkyl)2, -L-S(═O)2NH(C1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH2NH2, -L-C(═O)CH2OH, -L-C(═O)CH2SH, -L-C(═O)NHCN, -L-NHC(═O)ORo, -L-C(═O)NHRo, -L-NH(C═O)NHRo, -L-C(═O)N(Ro)2,... Agent: Myrexis, Inc.

20120225846 - Heterocyclic compounds for the inhibition of pask: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.... Agent: Bioenergenix

20120225847 - Squaric acid derivatives as inhibitors of the nicotinamide: The present application discloses novel squaric acid derivatives of the formula A: from —C(═O)—, —S(═O)2—, —C(═S)— and —P(═O)(R5)—; B: -, —O—, —NR6— and —C(═O)—NR6—; D: -, —O—, —CR7R8— and —NR9; m=0-12; n=0-12; m+n=1-20; p=0-2; R1: heteroaryl, aryl; R2: H, C1-12-alkyl, C3-12-cycloalkyl, —[CH2CH2O]1-10—(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, heteroaryl; R3: C1-12-alkyl, C3-12-cycloalkyl, —[CH2CH2O]1-10—(C1-6-alkyl),... Agent:

20120225848 - Antagonists of gaba-b receptors to enhance neuronal function, learning and memory: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a GABAB antagonist, or a blocker of Kir3.2 potassium channels, is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in... Agent:

20120225849 - 2-methoxyestradiol (2-me2) prodrug with enhanced bioavailability for prophylaxis or treatment of cancerous or non-cancerous condition: A prodrug of 2-methoxyestradiol (2-ME2) can be used for prophylaxis or treatment of cancer, such as esophageal cancer, prostate cancer, or breast cancer, and/or a non-cancerous condition, such as rheumatoid arthritis or pre-clampsia.... Agent: U.s. Department Of Veterans Affairs

20120225851 - Compositions and methods useful for treating diseases: The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia′, Ib′, Ic′, or II′ (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the... Agent: Eutropics Pharmaceuticals, Inc.

20120225850 - Steroidal antitubercular compounds: A steroidal compound n-hexyl-p-stigmasteryloxy-benzoate is reported as a novel potent antitubercular drug.... Agent:

20120225852 - Use of steroid compounds: s

20120225853 - Hormone replacement therapy and depression: The treatment and/or prevention of depression by the co-administration of an estrogen with the progestin dienogest for HRT and/or contraception.... Agent: Bayer Pharma Ag

20120225855 - Triazolopyridine jak inhibitor compounds and methods: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of... Agent:

20120225854 - Compounds that interact with glucokinase regulatory protein for the treatment of diabetes: c

20120225856 - Fused ring azadecalin glucocorticoid receptor modulators: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.... Agent: Corcept Therapeutics, Inc.

20120225857 - Mst1 kinase inhibitors and methods of their use: Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.... Agent:

20120225858 - 1,4 thiazepines/sulfones as bace1 and/or bace2 inhibitors: m

20120225859 - Pyrimidine derivatives used as pi-3 kinase inhibitors: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one... Agent: Novartis Ag

20120225860 - Method for administration of a gamma secretase inhibitor: There are provided a new dosage regimens for the gamma secretase inhibitor 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide which maximizes anti-tumor activity while maintaining acceptable toxicity levels.... Agent:

20120225861 - 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or... Agent:

20120225862 - Heteroaryl benzamides, compositions and methods of use: Provided are certain heteroaryl benzamides, compositions, and methods of their manufacture and use.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120225863 - Heterocyclic compounds for the inhibition of pask: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.... Agent: Bioenergenix

20120225864 - Methods and compositions for modulating tau levels: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating... Agent:

20120225865 - Arylcyclohexylethers of dihydrotetraazabenzoazulenes: wherein R1, R2 and R3 are as described herein, their manufacture, and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in... Agent:

20120225866 - Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation: e

20120225867 - Androgen receptor modulating compounds: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.... Agent:

20120225868 - Novel benzodioxole piperidine compounds: e

20120225869 - Compounds and compositions as inhibitors of cannabinoid receptor 1 activity: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).... Agent: Irm LLC

20120225870 - Methods for treating cancer resistant to erbb therapeutics: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also... Agent:

20120225872 - Methods of preparing and using quinazoline and quinoline derivatives: A method for treating cancer or inhibiting growth of cancer cells including administering to a patient mammal in need thereof a pharmaceutical preparation including the compound. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal including administering to a mammal... Agent:

20120225871 - Small-molecule modulators of trp-p8 activity: Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating... Agent: Dendreon Corporation

20120225876 - 8-azabicyclo[3.2.1]octane-8-carboxamide derivative: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R1a and R1b may be the same or different and each independently represents a C1-6 alkyl group which may be substituted by one... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20120225874 - Bicyclic derivatives as cetp inhibitors: s

20120225873 - Compounds for alzheimer's disease: The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH2, -L-C(═O)NH(C1-3 alkyl), -L-C(═O)N(C1-3 alkyl)2, -L-S(═O)2(C1-3alkyl), -L-S(═O)2NH2, -L-S(═O)2N(C1-3 alkyl)2, -L-S(═O)2NH(C1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH2NH2, -L-C(═O)CH2OH, -L-C(═O)CH2SH, -L-C(═O)NHCN, -L-NHC(═O)ORo, -L-C(═O)NHRo, -L-NH(C═O)NHRo, -L-C(═O)N(Ro)2, -L-NH(C═O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol),... Agent: Myrexis, Inc.

20120225875 - Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors: e

20120225877 - Substituted 1, 4-dioxa-8-azaspiro[4,5]decanes useful as fungicides and a process for the preparation thereof: This invention relates provides novel substituted 1,4-dioxa-8-azaspiro[4,5]decane of general formula (1), wherein R1 is selected from phenethyl, 4,6-dimethoxypyrimidin-2-yl and (2-chloro-5-thiazolyl)methyl and R2 is selected from the group consisting of hydroxy, 4-bromo-2-chlorophenoxy, morpholin-4-yl, (2-chloro-5-thiazolyl)methyloxy, benzyloxy, phenylsulfanyl, benzotriazol-1-yl and 5-chloro-2-fluoroanilino. The present invention also relates to a process for the preparation of... Agent:

20120225878 - Compounds: i

20120225879 - Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases:

20120225880 - Pyrazole compounds and thiazole compounds as protein kinases inhibitors:

20120225881 - Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hyrdroxy-2-amino-propionic acid amides and related compounds: The compounds shown by the structural formulas below have analgesic effect and are used in compositions and methods for treating mammal in need of such treatment.... Agent: Allergan, Inc.

20120225882 - Selective hydroxamate based mmp inhibitors: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be... Agent: Novartis Ag

20120225883 - Compounds for inflammation and immune-related uses: e

20120225884 - Bridged piperidine derivatives: m, and o or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and... Agent:

20120225885 - Imidazole derivatives and methods of use thereof: The present invention relates to novel imidazole compounds, pharmaceutical compositions comprising the imidazole compounds and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder,... Agent:

20120225886 - Novel pyrrolidine derived beta 3 adrenergic receptor agonists: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.... Agent: Merck Sharp & Dohme, Corp.

20120225887 - Glucokinase activators: e

20120225888 - Inhibitors of human immunodeficiency virus replication: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.... Agent: Bristol-myers Squibb Company

20120225889 - Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders: The present invention provides use of the compounds represented by formula (1): wherein, R1, R2, R3 and R4 are as defined in the specification, in all their stereo isomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and... Agent: Piramal Life Sciences Limited

20120225890 - Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed... Agent:

20120225891 - Amide derivatives, process for preparation thereof and use thereof as insecticide: s

20120225892 - [1,5]-diazocin derivatives: The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound for manufacturing a medicament. In particular the medicament and the pharmaceutical composition are intended to... Agent: Mellitech

20120225893 - Combination of an antipsychotic and an anti-inflammatory agent: The present invention relates to a pharmaceutical composition comprising an antipsychotic in combination with an anti-inflammatory agent, and to the use thereof in the treatment of psychotic disorder, and in particular, of schizophrenia.... Agent:

20120225894 - Substituted thienol[2,3-d] pyrimidines as hiv inhibitors: where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O,... Agent: Ardea Biosciences, Inc.

20120225895 - 1-heterodiene derivative and pest control agent: The present invention provides a pest control agent having a novel skeleton, which can be synthesized industrially, and also has excellent biological activity and residual effects. Specifically, the present invention provides a 1-heterodiene derivative represented by Formula (1) or a salt thereof, and a pest control agent including, as an... Agent: Nippon Soda Co., Ltd

20120225896 - Novel 2-pyridone derivative and pharmaceutical product containing same: Disclosed is a novel 2-pyridone derivative represented by general formula (1), which has both angiotensin II receptor antagonist activity and PPAR-γ activating activity and is useful as a prophylactic and/or therapeutic agent for cardiovascular diseases and metabolic diseases. Also disclosed is a pharmaceutical composition which contains the novel 2-pyridone derivative.... Agent: Kowa Company, Ltd.

20120225899 - Compounds and compositions as protein kinase inhibitors: s

20120225897 - Hair growth and/or regrowth compositions: The present disclosure relates to compositions containing certain pyrimidine compounds such as minoxidil and/or certain pyrimidine sulfate (inner salt) compounds such as minoxidil sulfate and especially compositions containing pyrimidine compounds in combination with an admixtures comprising at least one antioxidant, at least one organic acid and a select fatty acid... Agent: Mcneil-ppc, Inc.

20120225898 - Hair growth and/or regrowth compositions: The present disclosure relates to compositions containing certain pyrimidine compounds such as minoxidil and/or certain pyrimidine sulfate (inner salt) compounds such as minoxidil sulfate and especially compositions containing pyrimidine compounds in combination with an admixtures comprising at least one antioxidant, at least one organic acid and a select fatty acid... Agent: Mcneil-ppc, Inc.

20120225900 - N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an... Agent: Pfizer Inc.

20120225901 - Dosage form containing oxycodone and naloxone: The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, Cmax, AUCt value, mean bowel function score and/or duration of analgesic efficacy.... Agent: Euro-celtique S.a.

20120225902 - Methods for making 3-o-protected morphinones and 3-o-protected morphinone dienol carboxylates: e

20120225903 - Novel 2-substituted quinoline derivatives, and method for preparing same: The invention relates to 2-substituted quinoline derivatives, to a method for preparing same, and to the use thereof for drug production, particularly for treating infections caused by protozoa, such as leishmaniases, trypanosomiases, toxoplasmoses, and/or infections caused by retroviruses such as, for example, HIV or HTLV.... Agent:

20120225904 - New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one derivatives: This disclosure is directed to, inter alis, new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation, to pharmaceutical compositions comprising them, and to their use in therapy.... Agent:

20120225905 - Bepotastine compositions: Novel compositions including bepotastine besilate are provided such as sorbitol-free compositions, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.... Agent: Ista Pharmaceuticals, Inc.

20120225907 - Benzamide compounds useful as histone deacetylase inhibitors: or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions,... Agent: Astrazeneca Ab

20120225906 - Piperidine renin inhibitors:

20120225908 - Hydroxyl compounds and compositions for cholesterol management and related uses: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Esperion Therapeutics, Inc.

20120225909 - Indazole analog: e

20120225910 - Substituted heteroaryls:

20120225911 - Replenishing body stores of fat-soluble vitamins a, and d eradicate chronic viral infection: The invention relates to beta-carotene and its' related analogues, zinc, vitamin D3, and niacin to enhance the performance of the innate and adaptive immune system. Beta-carotene and its' related analogues are converted to retinoic acid that activates retinoic acid receptors, retinoid X receptors and niacin activates the retinoid X receptors... Agent:

20120225912 - Novel colchicine derivatives, methods and uses thereof: The invention relates to colchicine derivatives, methods and uses thereof for treatment of cancer. In certain embodiments, the colchicine derivative comprises a compound of Formula I:... Agent:

20120225914 - Treatment of sunburn using analgesics and antihistamines: Combination compositions and kits comprising an analgesic and an antihistamine are provided as well as methods of use in treating sunburn.... Agent: Sephoris Pharmaceuticals, LLC

20120225913 - Trypsin-like serine protease inhibitors, and their preparation and use: The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrein, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery... Agent: The Medicine Company (leipzig) Gmbh

20120225915 - Compositions and methods of using r(+) pramipexole: Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed.... Agent: Knopp Neurosciences Inc.

20120225916 - Compositions and methods to improve treatment of medical conditions using d-cycloserine: The invention describes methods and compositions for alleviating medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical compound that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction,... Agent:

20120225917 - Pest control composition: The present invention provides a pest control composition having an excellent controlling effect on pests, which comprises a combination of an ester compound represented by the formula (1): and a cyclic compound represented by the formula (2a) and/or a cyclic compound represented by the formula (2b).... Agent:

20120225918 - Compositions and methods for non-surgical treatment of ptosis: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical... Agent: Voom, LLC

20120225919 - Compositions and methods for non-surgical treatment of ptosis: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical... Agent: Voom, LLC

20120225920 - Compositions and methods for non-surgical treatment of ptosis: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical... Agent: Voom, LLC

20120225921 - Method of controlling phytopathogenic diseases on turfgrass: o

20120225923 - Dithiinetetra(thio)carboximides: The present invention relates to novel dithiinetetra(thio)carboximides, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.... Agent: Bayer Cropscience Ag

20120225922 - Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.... Agent: Qr Pharma

20120225934 - Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treatment of cancer thereof: Inclusion complex of deoxypodophyllotoxin of cyclodextrin, the preparation method and the use for the treatment of cancer thereof are disclosed. The inclusion complex consists of deoxypodophyllotoxin and beta-cyclodextrin derivative, wherein the molar ration of deoxypodophyllotoxin to beta-cyclodextrin derivative is 1:1-1:10. The beta-cyclodextrin derivative is sulfobutyl ether-beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin.... Agent:

20120225935 - Antimicrobial and radioprotective compounds: Disclosed is a method of treatment and/or prophylaxis of a microbial infection, employing compounds of formula (I), in which X and Y are either the same of different and selected from a hereroatiom; is a double or single bond depending on the heteroatoms X and Y; R1 to R5 are... Agent: Biodiem Ltd.

20120225936 - Method for producing triptolide: The invention relates to a method for producing triptolide from a suspension cell culture of Tripterygium sp., to a triptolide-enriched extract obtainable by means of extraction from the culture medium of an in vitro culture of dedifferentiated cells of the species Tripterygium, and to the therapeutic applications of said extract.... Agent: Pierre Fabre Medicament

20120225937 - Crystalline forms and processes for the preparation of pg12 receptor agonists: The present invention relates to salts of 2-(2-((4-(((4-chlorophenyl)(phenyl)-carbamoyloxy)methyl)cyclohexyl)methoxy)acetamido)ethanesulfonic acid (Compound 1) and crystalline forms, solvates and hydrates thereof. The present invention further relates to processes and intermediates useful in the preparation of Compound I and salts, solvates and hydrates thereof. Crystalline forms, salts, solvates and hydrates of the present invention... Agent: Arena Pharmaceuticals, Inc.

20120225938 - Method for treating central nervous system disorders: The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound.... Agent: Sucampo Ag

20120225939 - Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also... Agent: Novagali Pharma Sa

20120225940 - Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia: The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.... Agent: Metabolex, Inc.

20120225941 - Compositions and methods comprising c16:1n7-palmitoleate: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol... Agent: Tersus Pharmaceuticals, LLC

20120225942 - Synergistic antimicrobial agents: Synergistic antimicrobial compositions are provided by combining effective amounts of Nα-long chain alkanoyl di basic amino acid alkyl ester salts with glycerol monofatty acid esters resulting more effective anti-microbials and food preservatives.... Agent: Nevada Naturals, Inc.

20120225943 - Detergents capable of cleaning, bleaching, sanitizing and/or disinfecting textiles including sulfoperoxycarboxylic acids: The present invention relates to novel combined laundry detergent, bleach, and antimicrobial composition incorporating novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds used in compositions of the invention are storage stable, water soluble and have low to no odor. Compositions of the invention may... Agent: Ecolab Usa Inc.

20120225944 - Triacyglycerol-based alternative to paraffin wax: A triacylglycerol-based wax, which can be used in candle making, is provided. The triacylglycerol-based material is predominantly includes a triacylglycerol stock which has a fatty acid profile has no more than about 25 wt. % fatty acids having less than 18 carbon atoms. In addition, the fatty acid profile of... Agent: Elevance Renewable Sciences, Inc.

20120225945 - Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof: A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS,... Agent:

20120225946 - Choline fenofibrate delayed release compositions: Described are solid pharmaceutical compositions for oral administration comprising choline fenofibrate and an amount of an acid sufficient to substantially reduce a rate of dissolution of choline fenofibrate in an aqueous environment at pH 4.5 to less than about 50% in 2 hours. Processes for making the solid pharmaceutical composition... Agent:

20120225947 - Retinal neuroprotection by ion channel blockers regulated by the sur subunit: The present invention relates to the use of blockers of ion channels regulated by the SUR subunit, for the treatment and/or prevention of eye diseases associated with ischemia and/or retinal excitotoxicity.... Agent: Assistance Publique - Hopitaux De Paris

20120225948 - Broad spectrum disinfectant: A broad spectrum disinfectant includes a quaternary ammonium halogen, an alkaline agent, a chelating agent, a nonionic surfactant coupler, at least one alkoxylated nonionic surfactant, and water or any aliphatic alcohol. The disinfectant composition is phenol-free, is effective in eradicating microorganisms such as various fungi, and is stable to gamma-irradiation.... Agent: American Sterilizer Company

20120225949 - Compositions and methods for treating bipolar disorder: The present invention is directed to a method for treating symptoms associated with bipolar disorder. The method includes administering to a subject in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with bipolar disorder, childhood-onset bipolar disorder, or childhood-onset bipolar disorder with Fear of Harm.... Agent:

20120225951 - Parenteral administration of tapentadol: An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.... Agent: Gruenenthal Gmbh

20120225950 - Semisolid aqueous pharmaceutical composition containing tapentadol: A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.... Agent: Gruenenthal Gmbh

20120225952 - Non-aqueous silicone-based ophthalmic formulations: Non-aqueous compositions including a silicone based excipient and methods of their use are provided. The non-aqueous compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases... Agent:

20120225953 - Self-emulsifying active ingredient formulation and the use of this formulation: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying... Agent: Abbott Gmbh & Co. Kg

20120225955 - Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin: A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules (GAD, 1A2) and insulin, or one or more variants, analogues, derivatives or fragments thereof, and a kit for use... Agent: Rsr Limited

20120225954 - Methods and compositions for the classification of non-small cell lung carcinoma: wherein detecting a difference in the level of the at least one biomarker in the test sample compared to the control is indicative of whether the subject has or does not have non-small cell lung carcinoma or an increased likelihood of developing non-small cell lung carcinoma.... Agent: The Hospital For Sick Children

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.95051 seconds

PATENT INFO